Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 40269. Отображено 100.
05-01-2012 дата публикации

Biological control of nanoparticle nucleation, shape and crystal phase

Номер: US20120003629A9
Принадлежит: University of Texas System

The present invention includes compositions and methods for selective binding of amino acid oligomers to semiconductor and elemental carbon-containing materials. One form of the present invention is a method for controlling the particle size of the semiconductor or elemental carbon-containing material by interacting an amino acid oligomer that specifically binds the material with solutions that can result in the formation of the material. The same method can be used to control the aspect ratio of the nanocrystal particles of the semiconductor material. Another form of the present invention is a method to create nanowires from the semiconductor or elemental carbon-containing material. Yet another form of the present invention is a biologic scaffold comprising a substrate capable of binding one or more biologic materials, one or more biologic materials attached to the substrate, and one or more elemental carbon-containing molecules attached to one or more biologic materials.

Подробнее
12-01-2012 дата публикации

Tumor necrosis factor inhibiting peptides and uses thereof

Номер: US20120010158A1
Принадлежит: Panacea Biotec Ltd

The present invention relates to Tumor Necrosis Factor-alpha (TNF-alpha or TNF-α) inhibiting peptides and process for the preparation thereof. The present invention further relates to a pharmaceutical composition comprising TNF-alpha inhibiting peptides of the present invention and uses thereof in treating TNF-alpha mediated inflammatory disorders.

Подробнее
26-01-2012 дата публикации

Antibiotic peptides

Номер: US20120021975A1
Принадлежит: AMP Therapeutics GmbH and Co KG

The invention relates to a peptide or peptide derivative having the general formula: Sub 1 -X 1 -D 2 K 3 -P 4 -P 5 -Y 6 -L 7 -P 8 -R 9 -P 10 -X 2 -P 12 -P 13 -R 14 -X 3 -I 16 -P 17 /Y 17 -N 18 -N 19 -X 4 -Sub 2 , wherein X 1 is a non-polar, hydrophobic group or a positively charged group, D 2 is asparagine or glutamine, K 3 , X 2 , and X 4 are positively charged groups, X 3 is a positively charged group, proline, or a proline derivative; L 7 and I 16 are non-polar, hydrophobic groups, Y 6 and Y 17 are tyrosine, R 9 and R 14 are arginine, N 18 and N 19 are asparagine or glutamine, P 4 , P 5 , P 8 , P 10 , P 12 , P 13 , and P 17 are proline, hydroxyproline, or derivatives thereof, wherein possibly one or two of the groups selected from D 2 , P 4 , P 5 , P 8 , P 10 , P 12 , P 13 , P 17 , and Y 17 are replaced by an arbitrary group and/or P 13 and R 14 are exchanged, Sub 1 is the free or modified N-terminus, and Sub 2 is the free or modified C-terminus. The invention further relates to the use of the peptides and peptide derivatives in medicine, as an antibiotic, in a disinfectant or cleaning agent, as a preservative or in a packaging material, in pharmaceutical research, or in a screening method.

Подробнее
02-02-2012 дата публикации

Cancer therapy based on tumor associated antigens derived from cyclin d1

Номер: US20120027684A1
Принадлежит: IMMATICS BIOTECHNOLOGIES GMBH

The present invention relates to cyclin D1-derived peptides for use in the improved treatment of cancer in a patient, particularly in the form of a combination therapy using a vaccine. Other aspects relate to the use of the peptides or a combination thereof as a diagnostic tool.

Подробнее
02-02-2012 дата публикации

Apj receptor compounds

Номер: US20120028888A1
Принадлежит: ANCHOR THERAPEUTICS Inc

The invention relates generally to compounds which are allosteric modulators (e.g., negative and positive allosteric modulators, allosteric agonists, and ago-allosteric modulators) of the G protein coupled receptor apelin, also known as the APJ receptor. The APJ receptor compounds are derived from the intracellular loops and domains of the the APJ receptor. The invention also relates to the use of these APJ receptor compounds and pharmaceutical compositions comprising the APJ receptor compounds in the treatment of diseases and conditions associated with APJ receptor modulation, such as heart diseases (e.g., hypertension and tension and heart failure, such as congestive heart failure), cancer, diabetes, stem cell trafficking, fluid homeostasis, cell proliferation, immune function, obesity, metastatic disease, and HIV infection.

Подробнее
09-02-2012 дата публикации

Irak kinase family as novel target and biomarker for alzheimer

Номер: US20120035076A1

The present invention relates to methods and devices for the diagnosis or drug response prediction of neurological disorders by measuring kinase activity and studying the phosphorylation levels and profiles in samples of said patients. Furthermore the present invention relates to methods of identifying drug compounds relevant to neurological disorders by measuring kinase activity and studying phosphorylation levels. Also, the present invention relates to the use of inhibitors of the IRAK protein kinase family or a pharmaceutical composition thereof in the treatment of neurological disorders such as Alzheimer's disease.

Подробнее
16-02-2012 дата публикации

Mini-Hepcidin Peptides and Methods of Using thereof

Номер: US20120040894A1
Принадлежит: UNIVERSITY OF CALIFORNIA

Disclosed herein are peptides which exhibit hepcidin activity and methods of making and using thereof.

Подробнее
16-02-2012 дата публикации

Method for the manufacture of degarelix

Номер: US20120041172A1
Принадлежит: PolyPeptide Laboratories AS

In a step-wise synthesis of degarelix comprising 0.3% by weight or less of 4-([2(5-hydantoyl)]acetylamino)-phenylalanine analog on (solid support)-NH 2 a step comprises providing a solution of an amino acid or peptide of which the α-amino group is protected by Fmoc; contacting the support with the solution in the presence of reagent for forming a peptide bond between a carboxyl group of the amino acid or peptide and (solid support)-NH 2 ; removing Fmoc by contacting the support with an organic base, in particular piperidine, in an organic solvent. Also disclosed is degarelix of high purity prepared by the method of the invention and the use of Fmoc in the synthesis of degarelix.

Подробнее
23-02-2012 дата публикации

Substrate peptide sequences for plague plasminogen activator and uses thereof

Номер: US20120045474A1
Принадлежит: Individual

The present invention is directed to peptide sequences that were identified from combinatorial libraries and could serve as substrates of plague plasminogen activator (Pla). Another aspect of the present invention is drawn to peptides derived from the substrates for Pla as a result of chemical modifications leading to specific inactivation of the proteolytic activity of Pla. Additionally, the present invention is directed to the use of the substrates identified herein in the detection of bacteria expressing omptin family of proteases which includes Y. pestis . Furthermore, the present invention is also directed to the use of the inhibitors identified herein in the prevention and treatment of infection caused by these bacteria.

Подробнее
01-03-2012 дата публикации

Immunogenic epitopes of ngep antigen

Номер: US20120052116A1

The invention provides a peptide comprising a human cytolytic T lymphocyte (CTL) epitope from the human tumor-associated antigen (TAA) New Gene Expressed in Prostate (NGEP), which can be used in vaccine prevention or therapy of prostate cancer, as well as a nucleic acid encoding the peptide, a vector comprising the nucleic acid, a cell comprising the peptide, nucleic acid, or vector, and compositions thereof.

Подробнее
08-03-2012 дата публикации

Neuroprotective iron chelators and pharmaceutical compositions comprising them

Номер: US20120058945A1

Novel iron chelators exhibiting neuroprotective and good transport properties are useful in iron chelation therapy for treatment of a disease, disorder or condition associated with iron overload and oxidative stress, e.g., a neurodegenerative or cerebrovascular disease or disorder, a neoplastic disease, hemochromatosis, thalassemia, a cardiovascular disease, diabetes, an inflammatory disorder, anthracycline cardiotoxicity, a viral infection, a protozoal infection, a yeast infection, retarding aging, and prevention and/or treatment of skin aging and skin protection against sunlight and/or UV light. The iron chelator function is provided by a 8-hydroxyquinoline, a hydroxypyridinone or a hydroxamate moiety. The neuroprotective function is imparted to the compound, e.g., by a neuroprotective peptide. A combined antiapoptotic and neuroprotective function is provided by a propargyl group.

Подробнее
15-03-2012 дата публикации

Peptidomimetic protease inhibitors

Номер: US20120064034A1
Принадлежит: Vertex Pharmaceuticals Inc

The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.

Подробнее
22-03-2012 дата публикации

Method For Enucleating Nucleated Erythrocyte, And Enucleation Inducer

Номер: US20120070897A1
Принадлежит: KANAZAWA MEDICAL UNIVERSITY

Provided is a factor capable of inducing enucleation, which is a final stage of erythrocyte differentiation, within a short time. More particularly, provided are a method of inducing enucleation, which is a final stage of erythrocyte differentiation, within a short time by adding a compound derived from proopiomelanocortin (POMC) to an undifferentiated (nucleated) erythrocyte, and an enucleation inducer including the compound.

Подробнее
05-04-2012 дата публикации

Stabilized alpha helical peptides and uses thereof

Номер: US20120082636A1
Принадлежит: Individual

Novel polypeptides and methods of making and using the same are described herein. The polypeptides include cross-linking (“hydrocarbon stapling”) moieties to provide a tether between two amino acid moieties, which constrains the secondary structure of the polypeptide. The polypeptides described herein can be used to treat diseases characterized by excessive or inadequate cellular death.

Подробнее
05-04-2012 дата публикации

Methods for preventing and treating angioedema

Номер: US20120082676A1
Автор: Berhane Ghebrehiwet

One aspect of the present invention provides a method of treating or preventing angioedema in a patient in need thereof comprising administering to the patient a therapeutically effective amount of an agent that is capable of inhibiting the interaction of HK with gC1q-R. One aspect of the present invention provides a method of treating or preventing vascular permeability in a patient in need thereof comprising administering to the patient a therapeutically effective amount of an agent that is capable of inhibiting the interaction of HK with gC1q-R.

Подробнее
05-04-2012 дата публикации

Myostatin binding agents

Номер: US20120083442A1
Принадлежит: AMGEN INC

The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity.

Подробнее
19-04-2012 дата публикации

Polyion complex comprising hydrophobized polyamino acid and use of the same

Номер: US20120095186A1
Принадлежит: Kagoshima University NUC

A polyion complex (PIC) or a PIC nanoparticle that may be easily prepared, and that is finally disappeared in vivo due to its suitable biodegradability while exhibiting high stability in vivo, an immunotherapy agent comprising the PIC nanoparticle to which various antigen proteins or peptides may be easily conjugated or incorporated and/or which may be easily mixed with the antigen proteins or peptides, as well as a process for preparing thereof are provided. Specifically, a polyion complex (PIC) comprising a hydrophobized poly(acidic amino acid) and a basic polypeptide, a nanoparticle thereof having a particle shape, an immunotherapy agent comprising the PIC nanoparticle, as well as a process for preparing the PIC, comprising steps of introducing a hydrophobic amino acid to a poly(acidic amino acid) to prepare a hydrophobized poly(acidic amino acid), and dissolving the hydrophobized poly(acidic amino acid) prepared to a buffer, and it is mixed with a basic polypeptide dissolved in a buffer.

Подробнее
03-05-2012 дата публикации

Methods of administering pif agonist peptides and uses thereof

Номер: US20120107318A9
Автор: Eytan R. Barnea
Принадлежит: BioIncept LLC

A novel class of embryo derived peptides are described (Preimplantation factor) that were generated synthetically and were tested on peripheral blood immune cells and shown to block activated but not basal immunity, inhibiting cell proliferation and creating a T H 2 type cytokine bias, in addition PIF enhance endometrial receptivity by increasing adhesion molecules expression. PIF biological activity appears to be exerted by specific binding to inducible receptors present on the several white cell lineages. PIF peptides, which are immune modulators therefore may have diagnostic and non toxic therapeutic applications in improving fertility, reducing pregnancy loss as well may be useful when administered for the treatment of autoimmune diseases and for prevention xenotransplants rejection. Further, polyclonal antibodies against PIF peptides were generated that serve for precise measurements of PIF in biological fluids. They document pregnancy presence and viability as well it helps for monitoring pregnancies at risk in humans as well as in farm and non farm animals, improving animal husbandry, where currently no specific pregnancy test exists. Also the PIF antibodies may have additional therapeutic properties for treatment of HIV, and malaria.

Подробнее
03-05-2012 дата публикации

Methods and compositions for affecting the differentiation of clostridia in culture

Номер: US20120107916A1
Автор: Donald Mattsson
Принадлежит: Individual

The invention relates generally to methods and compositions for maintaining and manipulating microbial cultures of Gram-positive bacteria. Also provided are methods for identifying quorum sensing regulatory proteins and auto-inducing peptides in Gram-positive bacteria. Also provided are methods and compositions for affecting quorum sensing pathways of the genus Clostridium in culture including auto-inducing peptides to direct or maintain Clostridium cultures in a desired differentiated state. Differentiated states include extended serial propagation for the production of butanol or other fermentation products.

Подробнее
03-05-2012 дата публикации

Ligand-specific non-antibody compounds that inhibit cr2 activation and methods of use thereof

Номер: US20120108492A1
Принадлежит: University of Colorado

The present invention describes a novel non-antibody ligand-specific compound that selectively binds to a complement receptor type 2 (CR2) protein, a ligand thereof, or both, wherein the compound competitively inhibits CR2 ligand's binding to a CR2 protein in a standard assay. The present invention also describes compositions and methods of use thereof.

Подробнее
10-05-2012 дата публикации

Sparc-derived tumor rejection antigenic peptides and medicaments comprising the same

Номер: US20120115221A1
Принадлежит: ONCOTHERAPY SCIENCE INC

It is an objective of the present invention to identify SPARC protein-derived peptides that are able to induce human killer T cells and helper T cells having cytotoxic activity to tumors, and to provide a means for carrying out a tumor immunotherapy of patients with various types of cancers overexpressing SPARC. The present invention provides a peptide of any of the following: (A) a peptide which consists of the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3; or (B) a peptide which consists of an amino acid sequence comprising a substitution or addition of one or several amino acids with respect to the peptide consisting of the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3, and which has capacity to induce cytotoxic (killer) T cells.

Подробнее
17-05-2012 дата публикации

Protein conjugate having an endopeptidase- cleavable bioprotective moiety

Номер: US20120121613A1
Принадлежит: Bayer HealthCare LLC

The invention is directed to a procoagulant conjugate having an endopeptidase-activatable procoagulant protein moiety and one or more bioprotective moieties, which are conjugated to one another by a linker that is cleaved by an endopeptidase in situ to release the bioprotective moiety. The invention is also directed to therapeutic uses of the procoagulant conjugate and methods of making the conjugate.

Подробнее
17-05-2012 дата публикации

Peptide

Номер: US20120121625A1
Автор: David Wraith
Принадлежит: Apitope Technology Bristol Ltd

The present invention provides peptides at least partly derivable from FVIII which are capable of binding to an MHC class II molecule without further antigen processing and being recognised by a factor VIII specific T cell. In particular, the present invention provides a peptide comprising or consisting of the sequence EDNIMVTFRNQASR. The present invention also relates to the use of such a peptide for the prevention or suppression of inhibitor antibody formation in haemophilia A and/or acquired haemophilia.

Подробнее
24-05-2012 дата публикации

Induced pluripotent stem cells

Номер: US20120128655A1
Принадлежит: Mclean Hospital Corp

The present invention concerns the delivery of certain reprogramming factor proteins into cells, such as differenti-atedsomatic cells, in order to induce the epi-genetic reprogramming of the cell so it becomes a pluripotent stem cell. The reprogramming factor protein(s) may be Sox2, Klf4, Oct3/4, c-Myc, Lin28, Nanog, or any protein with reprogramming (-enhancing) activity. These proteins may be linked recombinantly or chemically to a cell penetrating peptide that helps facilitate the introduction of these proteins into the target cell and may be preferably expressed in mammalian cells to maintain them in active forms. Accordingly, the present method of inducing pluripotent stem cell (iPS) formation avoids the use of viral or DNA-based expression vectors or the expression of reprogramming factor genes within target cells, which are known to be harmful to the host target cell and cause cancer.

Подробнее
24-05-2012 дата публикации

Skin Permeating And Cell Entering (SPACE) Peptides and Methods of Use Thereof

Номер: US20120128756A1
Принадлежит: UNIVERSITY OF CALIFORNIA

The present disclosure provides peptides and peptide compositions, which facilitate the delivery of an active agent or an active agent carrier wherein the compositions are capable of penetrating the stratum corneum (SC) and/or the cellular membranes of viable cells.

Подробнее
31-05-2012 дата публикации

Peptides whose uptake in cells is controllable

Номер: US20120134922A1
Принадлежит: UNIVERSITY OF CALIFORNIA

Disclosed herein, in certain embodiments, is a selective transport molecule with increased in vivo circulation. In some embodiments, a selective transport molecule disclosed herein has the formula (A—X—B—C)n—M, wherein C is a cargo moiety; A is a peptide with a sequence comprising 5 to 9 consecutive acidic amino acids, wherein the amino acids are selected from: aspartates and glutamates; B is a peptide with a sequence comprising 5 to 20 consecutive basic amino acids; X is a linker; and M is a macromolecular carrier.

Подробнее
31-05-2012 дата публикации

Ttk peptides and vaccines including the same

Номер: US20120135020A1
Принадлежит: ONCOTHERAPY SCIENCE INC

Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the TTK gene that elicit CTLs are provided. Antigen-presenting cells and isolated CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing as active ingredients peptides derived from TTK or polynucleotides encoding the peptides. Furthermore, the present invention provides methods for the treatment and/or prophylaxis (i.e., prevention) of cancers (tumors), and/or the prevention of postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the peptides derived from TTK, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.

Подробнее
07-06-2012 дата публикации

Engineered cleavage half-domains

Номер: US20120142062A1
Принадлежит: Sangamo Biosciences Inc

Disclosed herein are engineered cleavage half-domains; fusion polypeptides comprising these engineered cleavage half-domains; polynucleotides encoding the engineered cleavage half-domains and fusion proteins; and cells comprising said polynucleotides and/or fusion proteins. Also described are methods of using these polypeptides and polynucleotides, for example for targeted cleavage of a genomic sequence.

Подробнее
14-06-2012 дата публикации

Detection and quantification of modified proteins

Номер: US20120149883A1
Принадлежит: Harvard College

The invention provides a method detecting and quantifying proteins by mass spectrophotometric analysis using peptide internal standards and provides a highly sensitive way of detecting protein modifications. In one aspect, the invention provides a method for determining a site of ubiquitination in a polypeptide and for evaluating ubiquitination targets in a population of polypeptides. In this way, a proteome ubiquitination map can be obtained which comprises information relating to the ubiquitination states of a plurality of cellular polypeptides. Maps can be obtained for a variety of different types of cells and cell states. For example, ubiquitination targets in normal and diseased cells can be evaluated. Preferably, the map is stored as data files in a database. Individual ubiquitinated polypeptides identified can be used to generate molecular probes diagnostic of a cell state and/or can serve as targets for agents that modulate one or more cellular processes.

Подробнее
28-06-2012 дата публикации

Zona pellucida binding peptides, expression vectors, compositions, and methods for species-specific immunocontraception of animals

Номер: US20120164165A1
Принадлежит: AUBURN UNIVERSITY

Disclosed are methods, compositions, zona pellucida binding peptides and polypeptides, and expression vectors for use in species-specific immunocontraception of animals. The disclosed compositions may include immunogenic compositions or vaccines.

Подробнее
05-07-2012 дата публикации

Novel Biologically Active Peptides and their New Uses

Номер: US20120171234A1
Автор: Kong Lam, Wai Ming Wong
Принадлежит: CMS Peptides Patent Holding Co Ltd

Novel peptides are disclosed with their use as a pharmaceutical composition. A method is also disclosed for making pharmaceutical compositions and treatment of an individual.

Подробнее
05-07-2012 дата публикации

Transglutaminase-activating peptide and cosmetic or pharmaceutial composition containing same

Номер: US20120172309A1
Принадлежит: Individual

The present invention relates to a peptide of general formula (I): R 1 -(AA) n -X 1 -X 2 -Arg-Arg-Gly-X 3 -X 4 -(AA) p -R 2 . The present invention also relates to a cosmetic or pharmaceutical composition, containing at least one peptide of general formula (I), in a physiologically suitable medium. The present invention also relates to the use of a composition containing the peptide of general formula (I) as an active ingredient which activates human transglutaminase to reinforce the skin barrier function and to stimulate epidermal regeneration and differentiation. The invention also relates to a cosmetic treatment method for preventing and/or for combatting external stresses and signs of skin ageing.

Подробнее
05-07-2012 дата публикации

In Vivo Polynucleotide Delivery Conjugates Having Enzyme Sensitive Linkages

Номер: US20120172412A1
Принадлежит: Arrowhead Madison Inc

The present invention is directed compositions for delivery of RNA interference (RNAi) polynucleotides to cells in vivo. The compositions comprise amphipathic membrane active polyamines reversibly modified with enzyme cleavable dipeptide-amidobenzyl-carbonate masking agents. Modification masks membrane activity of the polymer while reversibility provides physiological responsiveness. The reversibly modified polyamines (dynamic polyconjugate or DPC) are further covalently linked to an RNAi polynucleotide or co-administered with a targeted RNAi polynucleotide-targeting molecule conjugate.

Подробнее
12-07-2012 дата публикации

Novel compounds for inhibiting eef-2 kinase activity

Номер: US20120178769A1
Автор: Alexey G. Ryazanov

The present invention discloses novel compounds for inhibiting eEF2 kinase and methods of use thereof.

Подробнее
12-07-2012 дата публикации

Chromatographic processes and purified compounds thereof

Номер: US20120178900A1
Принадлежит: Biocon Ltd

The present disclosure demonstrates the utility of ion pairing agents in the preparative scale of purification. More particularly, the disclosure relates to the usage of ion pairing agents in RP preparative linear chromatography enabling high purity of the desired end product. The disclosure shows that ion-pairing agents have dramatic effect on desired purity of polypeptides.

Подробнее
23-08-2012 дата публикации

Isolating biological modulators from biodiverse gene fragment libraries

Номер: US20120214709A1
Принадлежит: Phylogica Ltd

The present invention provides a method for identifying a modulator or mediator of a biological activity, which activity includes antigenicity and or immunogenicity, said method comprising the step of: (i) producing a gene fragment expression library derived from defined nucleotide sequence fragments; and (ii) assaying the expression library for at least an amino acid sequence derived from step (i) for a biological activity wherein that activity is different from any activity the amino acid sequence may have in its native environment.

Подробнее
30-08-2012 дата публикации

Complex of a protein comprising zinc oxide-binding peptides and zinc oxide nanoparticles, and use thereof

Номер: US20120219504A1

The present invention relates to a complex of a protein comprising zinc oxide-binding peptides and zinc oxide nanoparticles, to the use thereof as a drug delivery carrier for manufacturing medicines, and to a vaccine composition and a contrast agent comprising the composite. The protein comprising zinc oxide-binding peptides significantly improves the in vivo availability of zinc oxide-binding peptides, and therefore the complex of the present invention can be used not only as a drug delivery carrier for in vivo drug delivery or intracellular drug delivery, but also for in vivo imaging or cell imaging. The complex can be used for producing separating agents for effectively separating biological materials, therapeutic agents for hyperthermia, etc., contrast agents for MRI, and beads applicable to biosensors.

Подробнее
30-08-2012 дата публикации

Unstructured recombinant polymers and uses thereof

Номер: US20120220011A1
Принадлежит: AMUNIX OPERATING INC

The present invention provides unstructured recombinant polymers (URPs) and proteins containing one or more of the URPs. The present invention also provides microproteins, toxins and other related proteinaceous entities, as well as genetic packages displaying these entities. The present invention also provides recombinant polypeptides including vectors encoding the subject proteinaceous entities, as well as host cells comprising the vectors. The subject compositions have a variety of utilities including a range of pharmaceutical applications.

Подробнее
13-09-2012 дата публикации

Polypeptides that bind tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods

Номер: US20120231013A1
Принадлежит: AMGEN INC

The present invention relates to TIMP-3 binding compositions, methods of producing such compositions, and methods of using such compositions, including in the treatment of various conditions.

Подробнее
20-09-2012 дата публикации

Compositions and methods for treating inflammation and fibrosis

Номер: US20120237504A1
Принадлежит: MAINE MEDICAL CENTER

The present invention features compositions featuring agents that bind to denatured collagen and methods of using such agents to treat or prevent fibrosis or inflammation in a subject.

Подробнее
20-09-2012 дата публикации

Production method of 11-sugar sialylglycopeptide

Номер: US20120238723A1
Принадлежит: Noguchi Institute

It is an object of the present invention to provide a method for producing an 11-sugar sialylglycopeptide easily and with good yield and a high degree of purity on an industrial scale from defatted bird egg yolks. The present invention provides a production method of an 11-sugar sialylglycopeptide. More specifically, the present invention provides a production method of an 11-sugar sialylglycopeptide comprising: an extraction step of extracting defatted bird egg yolks with water or a salt solution to obtain a liquid extract of a glycopeptide, a precipitation step of adding the liquid extract to a water-soluble organic solvent to precipitate the glycopeptide, and a desalting step of desalting the precipitate.

Подробнее
27-09-2012 дата публикации

Polypeptides having modulatory effects on cells

Номер: US20120245092A1
Принадлежит: ECOLE NORMALE SUPERIEURE DE LYON

The present invention relates to peptides and polypeptides having the sequence SAVTFAVCAL or variants thereof, capable of binding to Calcineurin and/or to NS5A-TP2 and to their use in therapy, as well as to nucleic acid sequences and vectors encoding these peptides and polypeptides, and to cells comprising said polypeptides, nucleic acid sequences or vectors. The invention further relates to the use of the peptides, polypeptides or their derivatives to bring about phenotypic changes in mammalian cells, particularly to up-regulate calcineurin activity. The invention finally relates to a method for intracellular identification of substances which bind to calcineurin and which modulate the physiological effects of calcineurin.

Подробнее
27-09-2012 дата публикации

Use of pedf-derived polypeptides for promoting stem cells proliferation and wound healing

Номер: US20120245097A1
Принадлежит: MACKAY MEMORIAL HOSPITAL

Disclosed herein is a synthetic peptide, which has an amino acid sequence that has 20-39 amino acid residues. The synthetic peptide has at least 80% amino acid sequence identity to SEQ ID NO: 1, and includes at least 20 consecutive residues that has at least 90% amino acid sequence identity to residues 11-30 of SEQ ID NO: 1. Also disclosed herein are compositions containing the synthetic peptide and applications thereof. According to various embodiments of the present disclosure, the synthetic peptide is useful in promoting stem cells proliferation or wound healing.

Подробнее
18-10-2012 дата публикации

Radiolabeled compound directable in vivo to target tissue and use thereof

Номер: US20120263645A1

The present invention provides a clinically usable radiolabeled compound that is precisely directable in vivo to a target tissue. The compound of the present invention has a first polypeptide or an analogue thereof, and a second polypeptide bonded to an N-terminus of the first polypeptide or the analogue thereof. In the compound, the first polypeptide is a polypeptide that specifically binds with a protein expressed in a target tissue, the second polypeptide has an amino acid region that has a high affinity for a radioactive metal nuclide, and the radioactive metal nuclide that has a high affinity for the amino acid region is held in the amino acid region.

Подробнее
08-11-2012 дата публикации

Peptide vaccines for cancers expressing mphosph1 or depdc1 polypeptides

Номер: US20120282286A1
Принадлежит: ONCOTHERAPY SCIENCE INC

The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: 7, 8, 9, 10, 11, 12, 192, 195, 197, 209, 225, 226, 228, 230, 240, 241, 243, 244, 249, 253, 254 or 255, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted, deleted, or added, wherein the peptides possess cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with the over-expression of MPHOSPH1 and/or DEPDC1, e.g. cancers, containing these peptides as an active ingredient. The peptides of the present invention can also be used as vaccines.

Подробнее
08-11-2012 дата публикации

Inhibitors of Atypical Protein Kinase C and Their Use in Treating Hedgehog Pathway-Dependent Cancers

Номер: US20120283194A1
Принадлежит: Leland Stanford Junior University

Methods and compositions are provided for modulating Hedgehog (Hh) pathway signaling in a cell. Aspects of the methods include methods for inhibiting Hh pathway-promoted cancer proliferation and/or metastasis that is promoted by Hh pathway signaling, methods for treating cancers promoted by Hh pathway signaling, and methods for screening candidate agents for the ability to treat a cancer promoted by Hh pathway signaling. In addition, reagents and kits thereof that find use in practicing the subject methods are provided.

Подробнее
08-11-2012 дата публикации

Attachment of biological targeting groups using metal free click chemistry

Номер: US20120283410A1
Принадлежит: Intezyne Technologies Inc

The present invention relates to the field of polymer chemistry and more particularly to click-functionalized targeting compounds and methods for using the same.

Подробнее
06-12-2012 дата публикации

Peptide bfp4 for promoting osteogenesis or vascularization and use thereof

Номер: US20120309675A1
Принадлежит: CHONNAM NATIONAL UNIVERSITY HOSPITAL

Disclosed are a peptide for promoting osteogenesis and vascularization, and the use thereof. The peptide has a low molecular weight so that it can be economically produced. In addition, it promotes osteoblastic differentiation, thus inducing osteogenesis. Further, the peptide can promote the expression of VEGF, resulting in vascularization. Accordingly, the peptide is useful for the prophylaxis or therapy of ischemic diseases.

Подробнее
06-12-2012 дата публикации

Peptides imparting cell permeability to lipid membrane structure and/or enhancing cell permeability of lipid membrane structure, and lipid membrane structure comprising lipid bound to such peptide as constituent lipid and having cell permeability or showing enhanced cell permeability

Номер: US20120309937A1
Принадлежит: Hokkaido University NUC

Provided are peptides imparting cell permeability to a lipid membrane structure and/or enhancing the cell permeability of a lipid membrane structure, and a lipid membrane structure which comprises, as a constituent lipid, a lipid bound to such a peptide and has cell permeability or shows enhanced cell permeability. The amino acid sequences of the peptides imparting cell permeability to a lipid membrane structure and/or enhancing the cell permeability of a lipid membrane structure are represented by: LX 1 X 2 X 1 X 1 X 1 L, LLX 2 X 1 X 1 X 1 L and LX 1 X 2 X 1 X 1 L (wherein L represents a leucine residue; X 1 represents a polar amino acid residue; and X 2 represents a polar, non-charged and branched chain amino acid residue).

Подробнее
20-12-2012 дата публикации

Methods for detection of botulinum neurotoxin

Номер: US20120322081A1
Принадлежит: Individual

Provided herein is a large immuno-sorbent surface area assay (ALISSA) for rapid and sensitive detection of toxin or enzyme activity. This assay is designed to capture a low number of toxin or enzyme molecules and to measure their intrinsic protease activity via conversion of a fluorigenic or luminescent substrate. The ALISSA is significantly faster and more sensitive than methods routinely utilized in the art. This assay is applicable for use for detection of a variety of toxins or enzymes having proteolytic activity, such as botulinum neurotoxin, bacillus anthracis lethal factor, human chitinases, and aspergillus fumigatus proteases. Also provided are methods for constructing and identifying novel luminescent or fluorescent substrates suitable for use with the ALISSA method.

Подробнее
27-12-2012 дата публикации

Kdr peptides and vaccines comprising the same

Номер: US20120328636A1
Принадлежит: ONCOTHERAPY SCIENCE INC

The present invention provides nonapeptides selected from peptides comprising the amino acid sequence of SEQ ID NO:2, 3, 5, 8, 11, or 12; nonapeptides or decapeptides selected from peptides comprising the amino acid sequence of SEQ ID NO:29, 30, 33, 34, 40, or 46; and peptides with cytotoxic T cell inducibility, in which one, two, or several amino acids are substituted or added to the above-mentioned amino acid sequences, as well as pharmaceuticals for treating or preventing tumors, where the pharmaceuticals comprise these peptides. The peptides of this invention can be used as vaccines.

Подробнее
27-12-2012 дата публикации

Heteropeptides useful for reducing nonspecific adsorption

Номер: US20120329986A1
Принадлежит: UNIVERSITE DE MONTREAL

Reagents, kits, uses and methods useful for example fo decreasing nonspecific adsorption of biomolecules at the surface of a solid support are disclosed. Such reagents and methods, which are based on short heteropeptides, may be used to decrease nonspecific adsorption in for example biosensing applications.

Подробнее
03-01-2013 дата публикации

Artificial peptide and use thereof

Номер: US20130005034A1
Принадлежит: TOAGOSEI CO LTD

Disclosed is a method for transforming human or non-human mammalian stem cells by introducing a desired peptide motif into the stem cells. The stem cell transformation method disclosed herein uses a synthesized peptide having an amino acid sequence which constitutes the desired peptide motif on the N-terminal end or C-terminal end of a cell membrane-permeable nucleolar localization signal sequence defined by the amino acid sequence KKRTLRKNDRKKR (SEQ ID NO:1).

Подробнее
10-01-2013 дата публикации

Hair-binding peptides

Номер: US20130011356A1
Принадлежит: EI Du Pont de Nemours and Co

Hair-binding peptides were isolated for their use in a variety of personal care formulations and applications. The isolation of hair-binding peptides was accomplished by enrichment using mRNA-display selection technology. Hair care compositions comprising peptide-based reagents prepared comprising the hair-binding peptides are also provided.

Подробнее
10-01-2013 дата публикации

Synthetic peptide amides

Номер: US20130012448A1
Принадлежит: Cara Therapeutics Inc

The invention relates to synthetic peptide amide ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low P 450 CYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure of formula I: Pharmaceutical compositions containing these compounds are useful in the prophylaxis and treatment of pain and inflammation associated with a variety of diseases and conditions. Such treatable pain includes visceral pain, neuropathic pain and hyperalgesia. Inflammation associated with conditions such as IBD and IBS, ocular and otic inflammation, other disorders and conditions such as pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma are treatable or preventable with the pharmaceutical compositions of the invention.

Подробнее
07-02-2013 дата публикации

Modified melk peptides and vaccines containing the same

Номер: US20130034574A1
Принадлежит: ONCOTHERAPY SCIENCE INC

Isolated peptides composed of the amino acid sequence of the modified MELK epitope peptide or immunologically active fragments thereof that bind to HLA antigens and have higher cytotoxic T lymphocyte (CTL) inducibility than that of the wild type MELK epitope peptide and thus are suitable for use in the context of cancer immunotherapy or endometriosis immunotherapy, more particularly cancer or endometriosis vaccines are described herein. The present invention further provides peptides that include one, two, or several amino acid insertions, substitutions or additions to the aforementioned peptides or fragments, but yet retain the requisite cytotoxic T cell inducibility. Further provided are nucleic acids encoding any of these aforementioned peptides as well as pharmaceutical substances and compositions including any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical substances and compositions of this invention find particular utility in the treatment of cancers, tumors, and endometriosis.

Подробнее
07-02-2013 дата публикации

Therapeutic peptides

Номер: US20130035296A1
Принадлежит: LYTIX BIOPHARMA AS

The present invention provides a peptide, peptidomimetic or amino acid derivative having a net positive charge of at least +2 and incorporating a disubstituted β amino acid, each of the substituting groups in the β amino acid, which may be the same or different, comprises at least (7) non-hydrogen atoms, is lipophilic and has at least one cyclic group, one or more cyclic groups within a substituting group may be linked or fused to one or more cyclic groups within the other substituting group and where cyclic groups are fused in this way the combined total number of non-hydrogen atoms for the two substituting groups is at least (12), for use as a cytolytic therapeutic agent; as well as non therapeutic uses of these molecules and certain defined novel compounds from within this definition.

Подробнее
07-03-2013 дата публикации

Egf receptor mimicking peptides

Номер: US20130059793A1
Принадлежит: University of Texas System

Provided are peptides which can mimic the epidermal growth factor receptor (EGFR), e.g., by selectively binding TGF-α and/or EGF. In certain embodiments, the peptides are retro-inverted peptides. The peptides may be used as soluble decoys for TGF-α and/or EGF, and anti-cancer properties of peptides are demonstrated both in vitro and in vivo. The peptides may be administered alone or comprised in a fusion construct, imaging construct, and/or a therapeutic construct, e.g., for the treatment of a cancer.

Подробнее
14-03-2013 дата публикации

Amphiphilic Peptides and Peptide Particles

Номер: US20130064895A1
Автор: Dittrich Christian

The inventions provided herein relate to amphiphilic peptides and particles comprising the amphiphilic peptides. Such amphiphilic peptides and particles described herein can be used as a delivery system, e.g., for therapeutic or diagnostic purposes, or as cell penetration vehicles or cell transfection agents. 1. An amphiphilic peptide comprising a hydrophobic peptidyl segment and a hydrophilic peptidyl segment ,wherein the hydrophobic peptidyl segment comprises an sequence of 2 to 10 alternating D- and L-amino acids selected from alanine, valine, isoleucine, leucine (Leu), phenylalanine, tyrosine or tryptophan (Trp), andwherein the hydrophilic peptidyl segment comprises charged, or uncharged but polar amino acids, or derivatives thereof.2. The amphiphilic peptide of claim 1 , wherein the hydrophobic peptidyl segment comprises an amino acid sequence of (Trp-Leu)-(Trp)or (Leu-Trp)-(Leu) claim 1 , wherein each Trp is D-Trp or L-Trp and each Leu is D-Leu or L-Leu claim 1 , m and p are independently an integer from 1 to 20 claim 1 , and n and q are independently 0 or 1 claim 1 , provided that when Trp is D-Trp then Leu is L-Leu claim 1 , and when Trp is L-Trp then Leu is D-Leu claim 1 , or vice versa.3. The amphiphilic peptide of claim 2 , wherein the amphiphilic peptide comprises at least one of the following characteristics:i. Trp is L-Trp;ii. m or p is between 1 and 3; or m or p is 3; andiii. n or q is 1.4. The amphiphilic peptide of claim 1 , wherein the hydrophilic peptidyl segment comprises at least one cationic or anionic charge present either on the N-terminus or an amino acid residue.5. The amphiphilic peptide of claim 4 , wherein the at least one cationic charge is in an amino acid residue selected from the group consisting of Lys claim 4 , Arg claim 4 , His claim 4 , and any combinations thereof; or wherein the at least one anionic charge is in an amino acid residue selected from the group consisting of Asp or Glu claim 4 , and any combinations thereof.6. The ...

Подробнее
21-03-2013 дата публикации

PEPTIDES MIMICKING HIV-1 VIRAL EPITOPES IN THE V2 LOOP FOR THE GP120 SURFACE ENVELOPE GLYCOPROTEIN

Номер: US20130071424A1
Принадлежит: New York University

The present invention relates to an isolated immunogenic peptide comprising a V2 loop fragment from HIV surface envelope glycoprotein gp120. This peptide binds specifically with antibodies in blood of patients vaccinated with a vaccine that has shown protection from HIV-1 infection, does not react with blood of matched patients who did not receive the vaccine, and can, therefore, elicit anti-HIV-1 antibodies which protect against HIV-1 infection. Other aspects of the present invention relate to an isolated immunogenic polypeptide comprising the peptide inserted into an immunogenic scaffold protein, a vaccine composition comprised of the immunogenic peptide and an immunologically or pharmaceutically acceptable vehicle or excipient as well as methods of inducing an immune response against HIV-1 and methods of detecting HIV-1. 1. An isolated immunogenic peptide comprising a V2 loop fragment from HIV surface envelope glycoprotein gp120 which binds specifically with antibodies in blood of patients vaccinated with a vaccine that has shown protection from HIV-1 infection , does not react with blood of matched patients who did not receive the vaccine , and can , therefore , elicit anti-HIV-1 antibodies which protect against HIV-1 infection.2. The isolated immunogenic peptide of claim 1 , wherein the peptide comprises the amino acid sequence of SEQ ID NO: 1.3. The isolated immunogenic peptide of claim 2 , wherein the peptide comprises the amino acid sequence of SEQ ID NO: 7.4. The isolated immunogenic peptide of claim 2 , wherein the peptide comprises the amino acid sequence of SEQ ID NO: 11.5. The isolated immunogenic peptide of claim 2 , wherein the peptide comprises the amino acid sequence of SEQ ID NO: 12.6. The isolated immunogenic peptide of claim 2 , wherein the peptide comprises the amino acid sequence of SEQ ID NO: 13.7. The isolated immunogenic peptide of claim 2 , wherein the peptide comprises the amino acid sequence of SEQ ID NO: 14.8. The isolated immunogenic ...

Подробнее
21-03-2013 дата публикации

PEPTIDES, CONJUGATES AND METHOD FOR INCREASING IMMUNOGENICITY OF A VACCINE

Номер: US20130071428A1
Принадлежит:

The present invention relates to conjugates comprising a peptide of at least 10 amino acid residues comprising the amino acid sequence GITELKKL for induction of potent humoral and cellular immune responses when administered to subjects having antibodies against tetanus toxoid. In one embodiment the invention relates to a prophylactic and therapeutic vaccine and in a further embodiment the invention relates to the treatment or prevention of cancer or an infectious disease. 1. A conjugate , comprising a peptide conjugated to an antigen , immunogen or to a vehicle comprising an antigen or immunogen , wherein the peptide comprises:(i) at least 10 amino acid residues of SEQ ID NO:3 that comprise the amino acid sequence GITELKKL; or,(ii) an amino acid sequence having at least 80% sequence identity with an amino acid sequence as provided under (i) and wherein the peptide, when subjected to serum samples from at least 10 human subjects that had been vaccinated with tetanus toxoid is in at least 50% of the serum samples bound by antibodies from the serum samples, as determined in a Tettox ELISA;wherein the peptide is not the tetanus toxin beta chain.2. The conjugate according to claim 1 , wherein the peptide comprises less than 100 amino acid residues.3. The conjugate according to claim 1 , wherein the antigen claim 1 , the immunogen or the vehicle comprising the antigen or immunogen is conjugated to the C-terminus of the peptide.4. The conjugate according to claim 1 , wherein 2 to 20 peptides are bound to the antigen claim 1 , immunogen or the vehicle comprising the antigen or immunogen.5. A pharmaceutical composition comprising a conjugate according .6. A method for prevention or treatment of cancer or an infectious disease in a subject claim 1 , comprising administering to a subject in need thereof a conjugate according to .7. (canceled)8. The method according to claim 6 , wherein the subject has antibodies against tetanus toxin or tetanus toxoid.9. The method according ...

Подробнее
21-03-2013 дата публикации

CARDIOVASCULAR THERAPEUTICS

Номер: US20130072431A1
Принадлежит: OTAGO INNOVATION LIMITED

Compounds and compositions comprising a B-type natriuretic signal peptide fragment agent, and methods of use thereof, are provided for the treatment or prevention of cardiovascular diseases, disorders, and conditions. 1. A pharmaceutical composition for use in preventing and/or treating a cardiovascular disorder , comprising a therapeutically effective amount of a Type-B natriuretic signal peptide fragment agent and a pharmaceutically acceptable carrier.2. A pharmaceutical composition according to claim 1 , wherein said Type-B natriuretic signal peptide fragment agent is BNPsp(17-26) (SEQ ID NO:1).3. A pharmaceutical composition according to claim 1 , wherein said Type-B natriuretic signal peptide fragment agent comprises a sequence selected from SEQ.ID.NOS:2 to 9.4. A pharmaceutical composition according to claim 1 , wherein said composition is suitable for parenteral administration.5. A pharmaceutical composition according to claim 1 , wherein said parenteral administration is infusion.6. A pharmaceutical composition according to claim 1 , wherein said composition is suitable for slow claim 1 , delayed or controlled release administration.7. A pharmaceutical composition according to wherein said cardiovascular disorder is an acute coronary syndrome.8. A pharmaceutical composition according to wherein said cardiovascular disorder is a heart failure or an ischemic heart disease.9. A pharmaceutical composition according to claim 1 , wherein said Type-B natriuretic signal peptide fragment agent comprises a Type-B natriuretic signal peptide fragment analog.10. A pharmaceutical composition according to claim 1 , wherein said Type-B natriuretic signal peptide fragment agent comprises a peptide selected from the group consisting of a peptide according to any one of Formulae I-VIII.11. A substantially pure peptide having the amino acid sequence selected from the group consisting of:{'sub': 1', '2', '3', '4', '5', '6', '7', '8, 'a. L H XXXXXXXX(SEQ ID NO: 19)'}{'sub': 1', ' ...

Подробнее
21-03-2013 дата публикации

Secreted Protein Acidic and Rich in Cysteine (SPARC) Protein SRM Assay

Номер: US20130072581A1
Принадлежит:

The current disclosure provides for specific peptides from the Secreted Protein Acidic and Rich in Cysteine (SPARC) protein and the derived ionization characteristics of those peptides that are advantageous for quantifying SPARC directly in formalin fixed biological samples by the method of Selected Reaction Monitoring (SRM) mass spectrometry. Such fixed biological samples include: formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and formalin fixed and paraffin embedded tissue culture cells. SPARC protein is quantitated in biological samples by the method of SRM/MRM mass spectrometry by quantitating one or more of the peptides described herein. The peptides can be quantitated if they reside in a modified or an unmodified form. Examples of potentially modified forms of SPARC peptides include those bearing phosphorylation of a tyrosine, threonine, serine, and/or other amino acid residues within the peptide sequence. 1. A method for measuring the level of the Secreted Protein Acidic and Rich in Cysteine (SPARC) protein in a biological sample , comprising detecting and/or quantifying the amount of one or more modified or unmodified SPARC fragment peptides in a protein digest prepared from said biological sample using mass spectrometry; and calculating the level of modified or unmodified SPARC protein in said sample; andwherein said level is a relative level or an absolute level.20. The method of claim , further comprising the step of fractionating said protein digest prior to detecting and/or quantifying the amount of one or more modified or unmodified SPARC fragment peptides.34-. (canceled)5. The method of claim 1 , wherein said protein digest comprises a protease digest.68-. (canceled)9. The method of claim 1 , wherein the SPARC fragment peptide comprises an amino acid sequence as set forth as SEQ ID NO:1 claim 1 , SEQ ID NO:2 claim 1 , SEQ ID NO:3 claim 1 , SEQ ID NO:4 claim 1 , SEQ ID ...

Подробнее
28-03-2013 дата публикации

IGA-BINDING PEPTIDE AND PURIFICATION OF IGA USING THE SAME

Номер: US20130078741A1
Автор: Ito Yuji
Принадлежит:

This invention relates to: a peptide which comprises an amino acid sequence consisting of 12 to 18 amino acid residues represented by (X)—C—(X)—C—(X) wherein each X independently represents an arbitrary amino acid residue other than cysteine, and C represents a cysteine residue, and is capable of binding to human IgA; and to a method for analyzing or purifying human IgA using the peptide. 118-. (canceled)19. A peptide which comprises an amino acid sequence consisting of 12 to 18 amino acid residues represented by the following formula I and is capable of binding to human IgA:{'br': None, 'sub': 1-3', '8-10', '1-3, '(X)—C—(X)—C—(X)\u2003\u2003(I)'}wherein each X independently represents an arbitrary amino acid residue other than cysteine; and C represents a cysteine residue.20. The peptide according to claim 19 , wherein the peptide comprises an amino acid sequence consisting of 16 to 18 amino acid residues represented by the following formula II and is capable of binding to human IgA:{'br': None, 'sub': 3', '7-9', '3, '(X)—C-L-(X)—C—(X)\u2003\u2003(II)'}wherein each X independently represents an arbitrary amino acid residue other than cysteine; C represents a cysteine residue; and L represents a leucine residue, and wherein the 9th and 10th amino acid residues Xs counted from the N terminus in the case that the number of amino acid residues of the peptide is regarded as 18 amino acid residues, each independently represent an arbitrary amino acid residue other than cysteine, or either of the 9th and 10th amino acid residues Xs, or both, are deleted.21. The peptide according to claim 19 , wherein the peptide comprises an amino acid sequence consisting of 16 to 18 amino acid residues represented by the following formula II and is capable of binding to human IgA:{'br': None, 'sub': 3', '7-9', '3, '(X)—C-L-(X)—C—(X)\u2003\u2003(II)'}wherein each X independently represents an arbitrary amino acid residue other than cysteine; C represents a cysteine residue; and L ...

Подробнее
28-03-2013 дата публикации

Method for prepairing peptide inhibitors of a lipid-activated enzyme and peptides produced by same

Номер: US20130079493A1
Автор: Kinnunen Paavo
Принадлежит: ESTAJA OY

The present invention is based on the discovery of a mechanism mediating the formation of amyloid-type aggregates of lipid-activated enzymes. The invention discloses a method for preparing inhibitors of said enzymes and provides peptide inhibitors having potential for therapeutic use. The method comprises the identification of aggregation-prone regions in the amino acid sequence of the enzyme by the use of a suitable computer algorithm and designing a peptide based on the found aggregation-prone region. 1. A method for preparing peptide inhibitors of a lipid-activated enzyme , the method comprising the steps of:a) identifying aggregation-prone regions in amino acid sequence of said enzyme by the use of a suitable computer algorithm;b) designing a peptide based on the aggregation-prone region found in step a), wherein said peptide comprises the sequence of said region or a part thereof;c) synthesizing the peptide designed in step b); andd) contacting the peptide obtained in step c) with said lipid-activated enzyme and measuring the activity of said enzyme, wherein said peptide is an inhibitor of said enzyme, if the activity of the enzyme is decreased in the presence of said peptide.2. The method according to claim 1 , wherein said lipid-activated enzyme is selected from the group consisting of phospholipases claim 1 , myeloperoxidase claim 1 , acid sphingomyelinase claim 1 , heat shock protein 70 and PAF acetylhydrolase.3. The method according to claim 2 , wherein said lipid-activated enzyme is bee-venom phospholipase A2 and the peptide designed in step b) is SYFVGKMYFNLI (SEQ ID NO:2).4. The method according to claim 2 , wherein said lipid-activated enzyme is phospholipase A2 in human tears and the peptide designed in step b) is TKFLSYK (SEQ ID NO:3).10. A peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS:1-68.11. The peptide according to comprising amino acid sequence KMYFNLI (SEQ ID NO:1).12. The peptide according to ...

Подробнее
04-04-2013 дата публикации

OLIGOMER-SPECIFIC AMYLOID BETA EPITOPE AND ANTIBODIES

Номер: US20130084283A1
Автор: Cashman Neil R.
Принадлежит:

A novel constrained peptide epitope derived from Aβ, wherein the eptitope comprises the amino acid sequence SNK, related antibody compositions and methods of use. An isolated antibody that specifically binds to a cyclic peptide comprising the conformational epitope which comprises the amino acid sequence SNK and corresponding to a solvent-exposed, antibody accessible knuckle region of oligomeric Aβ is described. An antigenic peptide comprising an epitope having a constrained cyclic configuration, which comprises the amino acid sequence SNK and corresponding to a solvent-exposed, antibody accessible knuckle region of oligomeric Aβ is also described. Methods of treating, preventing and diagnosing Alzheimer's disease are also described. 1. An isolated antibody that specifically binds to a cyclic peptide derived from Aβ , wherein the cyclic peptide comprises a conformational epitope having an amino acid sequence of at least SNK corresponding to a solvent-exposed , antibody accessible knuckle region of oligomeric Aβ.2. An isolated antibody that specifically binds to a cyclic peptide derived from Aβ , wherein the cyclic peptide comprises a conformational epitope having an amino acid sequence corresponding to SEQ ID NO: 1 corresponding to a solvent-exposed , antibody accessible knuckle region of oligomeric Aβ.3. The isolated antibody of or , wherein the antibody specifically binds with greater affinity to an oligomeric form of Aβ than to a non-oligomeric form of Aβ.4. The isolated antibody of any of to , wherein the antibody is monoclonal.5. The isolated antibody of any of to , wherein the antibody is humanized.6. An antigenic peptide comprising an epitope having a constrained cyclic configuration , wherein the epitope having an amino acid sequence of at least SNK corresponding to a solvent-exposed , antibody accessible knuckle region of oligomeric Aβ.7. An antigenic peptide comprising an epitope having a constrained cyclic configuration , wherein the epitope having an ...

Подробнее
04-04-2013 дата публикации

PEPTIDES SHARED AMONG LETHAL CANCERS AND THERAPEUTIC COMPOSITIONS COMPRISING SAID PEPTIDES

Номер: US20130084303A1
Принадлежит:

The present invention provides cancer peptides related to rapid replication and shared among different histological cancer types. The peptides are provided in compositions for interfering with replication in cancer, in preventive and therapeutic vaccines, and in diagnostic applications. The compositions for interfering with replication in cancer are useful for preventing and treating different histological types of cancer including ectodermic, endodermic, and mesodermic cancers as well as cancers arising in association with HIV. 1. A composition for interfering with replication of cancer comprising at least one sequence of SEQ ID NO(s): 1-203.2. The composition of comprising at least one peptide consisting essentially of at least one of SEQ ID NO(s): 1-203.3. The composition of comprising a mixture of at least two peptides of SEQ ID NO(s): 1-27 claim 1 , SEQ ID NO(s): 28-52 claim 1 , SEQ ID NO(s): 53-103 claim 1 , SEQ ID NO(s): 104-148 claim 1 , SEQ ID NO(s): 149-165 claim 1 , and SEQ ID NO(s): 166-203.4. The composition of comprising a protein comprising at least one sequence of SEQ ID NO(s): 1-203.5. The composition of claim 1 , wherein said composition is for direct or indirect interference with replication of cancer.6. The composition of claim 5 , wherein said composition is for indirect interference with cancer where the indirect interference is mediated by an immune response.7. An isolated or synthesized protein fragment or peptide comprising at least one of SEQ ID NO(s): 1-203 or a sequence sharing at least 70% identity with at least one of SEQ ID NO(s): 1-203.8. The isolated or synthesized protein fragment or peptide of consisting essentially of a peptide of at least one of SEQ ID NO(s): 1-203.9. The isolated or synthesized protein fragment or peptide of consisting of at least one of SEQ ID NO(s): 1-203.10. A vaccine comprising at least one of SEQ ID NO(s): 1-27 claim 7 , SEQ ID NO(s): 28-52 claim 7 , SEQ ID NO(s): 53-103 claim 7 , SEQ ID NO(s): 104-148 ...

Подробнее
04-04-2013 дата публикации

PHENOLIC BINDING PEPTIDES

Номер: US20130084618A1
Принадлежит: DANISCO US INC.

The present application relates to peptides which bind to tannin, polyphenolic or anthocyanin compounds, and particularly to tea and wine stains on a fabric or other surface. The invention also concerns binding peptide conjugates which includes a binding peptide coupled to an agent and the use of the binding peptide conjugate for delivering an agent to a desired target. 1. A binding peptide comprising an amino acid sequence shown in any one of SEQ ID NOs. 1-316 and a binding peptide having at least 70% sequence identity thereto.2. (canceled)3. The binding peptide of claim 1 , wherein the peptide is selected from the group consisting of KTPSPHG (SEQ ID NO. 1); PNTTRHS (SEQ ID NO. 2); LWTSPQL (SEQ ID NO. 8); TNNTSPT (SEQ ID NO. 24); SPTSTNS (SEQ ID NO. 43); TTTTPFA (SEQ ID NO. 77); SWNTSPL (SEQ ID NO. 80); QAVKASHATMYL (SEQ ID NO. 97); SYDLIPPRSGLA (SEQ ID NO. 104); DPNTTSH (SEQ ID NO.118); KASHLVP (SEQ ID NO: 132); LPTSTLT (SEQ ID NO. 139); QNQKSTT (SEQ ID NO. 158); SIIPPRQ (SEQ ID NO. 168); WSNKPLSPNDLR (SEQ ID NO. 193) and peptides having at least 75% amino acid sequence identity thereto.4. The binding peptide of claim 1 , having a repeatable motif selected from the group consisting ofLPL (SEQ ID NOs. 120, 123, 115 and 250);FAT (SEQ ID NOs. 125, 227 and 235);STT (SEQ ID NOs. 90, 158, 230 and 310);HSP (SEQ ID NOs. 18, 252 and 307);TNK (SEQ ID NOs. 40, 259 and 287);SPL (SEQ ID NOs. 53, 80, 152, 229, 232 and 292);THS (SEQ ID NOs. 62, 209 and 290);TSP (SEQ ID NOs. 8, 24, 80, 223 and 291);SPT (SEQ ID NOs. 24, 43 and 266);AQT (SEQ ID NOs. 59, 134 and 205);NSS (SEQ ID NOs. 31, 86, 213, 227 and 278);PAL (SEQ ID NOs. 109, 224 and 256);SGL (SEQ ID NOs. 104, 284 and 298); andTQT (SEQ ID NOs. 105, 281 and 287) and a binding peptide having the repeatable motif and at least 75% amino acid sequence identity to a binding peptide having the repeatable motif and listed herein.5. The binding peptide of claim 1 , wherein said peptide binds to a compound selected from the group ...

Подробнее
04-04-2013 дата публикации

Treatments for Gastrointestinal Disorders

Номер: US20130085107A1
Принадлежит: IRONWOOD PHARMACEUTICALS, INC

The present invention provides peptides that are useful for the treatment of gastrointestinal disorders. The present invention also provides compositions and methods of treating gastrointestinal disorders and pharmaceutical compositions for accomplishing the same. In some embodiments, these pharmaceutical compositions include oral dosage forms. 183-. (canceled)84. A peptide or a pharmaceutically acceptable salt thereof , wherein the peptide comprises the amino acid sequence{'sub': 1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11', '12', '13', '14', '15', '16', '17, 'XaaXaaXaaXaaCysXaaXaaXaaCysAsnProAlaCysXaaGlyXaaXaa, or a pharmaceutically acceptable salt thereof; wherein'}{'sub': '1', 'Xaais Asn, D-Asn, Gln, D-Gln, Pro, Ala, n-Ala, D-Ala, Val, D-Val, Gly, Thr, D-Thr, Asp, D-Asp, γ-carboxylated Asp, Glu, D-Glu, γ-carboxylated Glu, α-aminosuberic acid (Asu), α-aminoadipic acid (Aad), α-aminopimelic acid (Apm), or is absent;'}{'sub': '2', 'Xaais Asp, γ-carboxylated Asp, Glu, γ-carboxylated Glu, Asu, Aad, Apm, or is absent;'}{'sub': '3', 'Xaais Asp, γ-carboxylated Asp, Glu, γ-carboxylated Glu, Asu, Aad, Apm, or is absent;'}{'sub': '4', 'Xaais Cys or D-Cys;'}{'sub': '6', 'Xaais P-Ser, P-Thr, P-homo-Ser, 4-hydroxyvaline phosphate, P-homo-Thr, P-Cys or P-Tyr;'}{'sub': '7', 'Xaais Tyr, Leu, Phe or Ile;'}{'sub': '8', 'Xaais Cys or D-Cys;'}{'sub': '14', 'Xaais Thr, Ala or Phe;'}{'sub': '16', 'Xaais Cys or D-Cys; and'}{'sub': '17', 'Xaais Tyr, D-Tyr, or is absent;'}wherein:{'sub': 1', '1, 'if Xaais present, Xaamay be modified on its amino group by methyl, ethanedioic acid, propanedioic acid, butanedioic acid, pentanedioic acid, hexanedioic acid, heptanedioic acid or octanedioic acid;'}{'sub': 1', '2', '2, 'if Xaais absent and Xaais present, then Xaamay be modified on its amino group by methyl, ethanedioic acid, propanedioic acid, butanedioic acid, pentanedioic acid, hexanedioic acid, heptanedioic acid or octanedioic acid; or'}{'sub': 1', '2', '3, 'if both Xaaand Xaaare ...

Подробнее
04-04-2013 дата публикации

PEPTIDES FOR PROMOTING ANGIOGENESIS AND AN USE THEREOF

Номер: US20130085108A1
Принадлежит:

The present invention relates to a peptide promoting angiogenesis and novel use thereof. More particularly, the invention relates to peptides promoting angiogenesis, and the use of the peptide for promoting angiogenesis and preventing or treating angiogenesis-related disease. The peptide of the present invention have an excellent effect on promoting angiogenesis. Accordingly, it is useful for preventing or treating angiogenesis-related disease and for preparing regeneration of skin flap, wound and burn healing, implantation of artificial-skin and preparation of blood vessels for transplantation. 1. An isolated peptide comprising an amino acid sequence represented by the general formula (I):{'br': None, '[N-terminus-X1 X2 X3 X4 X5 X6 X2′ X1′-C-terminus]\u2003\u2003(I)'}whereineach of X1 and X1′ is independently non-existence or a basic amino acid,each of X2 and X2′ is independently non-existence or a polar amino acid,X3 is alanine,X4 is glycine,X5 is a charged amino acid, andX6 is serine.2. The isolated peptide of claim 1 , wherein the peptide further comprises proline in N-terminal of the general formula (I).3. The isolated peptide of claim 1 , wherein the peptide comprises any one amino acid sequence selected from the group consisting of the amino acid sequences represented by SEQ ID NO: 1 to 7.4. The isolated peptide of claim 1 , wherein the peptide is amidated at the C-terminal end thereof.5. A composition for promoting angiogenesis comprising the peptide of as an active ingredient.6. The composition of claim 5 , wherein the composition is for regeneration of skin flap claim 5 , wound and burn healing claim 5 , implantation of artificial skin or preparation of blood vessels for transplantation.7. A pharmaceutical composition for prevention or treatment of angiogenesis-related diseases selected from a group consisting of diabetic retinopathy claim 1 , retinopathy of prematurity claim 1 , age-related macular degeneration claim 1 , glaucoma claim 1 , diabetic foot ...

Подробнее
04-04-2013 дата публикации

PEPTIDE NETWORKS

Номер: US20130085188A1
Принадлежит: The University of Queensland

Methods of modulating interfacial characteristics in a self-assembled, force-transmitting peptide network at a fluid-fluid interface are disclosed. The methods involve exposing a peptide capable of participating in a self-assembled, force-transmitting peptide network, either before or after it interacts with other peptides to form the peptide network to a stimulus that alters the chemical and/or physical properties of the peptide. Use of such methods in applications such as emulsions and foams are also disclosed. 1. A method of modulating force transmission in a self-assembled , force-transmitting peptide network at a fluid-fluid interface , said method comprising exposing a peptide capable of participating in said network , either before or after it interacts with other peptides to form the peptide network , to a stimulus that alters the chemical and/or physical properties of the peptide , wherein:(i) the force-transmitting peptide network has an interfacial elasticity modulus greater than or equal to 30 mN/m, and a maximum interfacial stress of greater than 0.5 mN/m;(ii) the stimulus is selected from an acid, a base, a metal ion, a chelating agent, an organic or inorganic counterion, a chaotropic agent, a salt, temperature or mixtures thereof; and (a) an amphipathic α-helix having the sequence (abcdefg)n or (gabcdef)n wherein residues a and d are hydrophobic amino acid residues, at least one of residues b, c, e, and g is an ionisable amino acid residue that may be modulated by protonation and deprotonation, residue f is a hydrophilic amino acid residue and n is an integer of 2 to 5; and', '(b) a β-sheet having a hydrophobic face and a hydrophilic face selected from the group of SEQ ID Nos:6, 7, 8, 11 and 12,, '(iii) the peptide is an amphipathic peptide 5 to 60 amino acid residues in length capable of forming at the fluid-fluid interface an ordered secondary structure selected from(iv) the peptide has an affinity for the fluid-fluid interface, wherein one phase of ...

Подробнее
04-04-2013 дата публикации

Method for the identification of t cell epitopes

Номер: US20130085260A1

A novel method to identify relevant T-cell epitopes recognized by CD8 + or CD4 − T lymphocytes is described. The method is based on the use of mRNA fragments synthesized from cDNA encoding portions of a polypeptide of interest. mRNA fragments are introduced into antigen-presenting cells to deduce an epitope's localization in a polypeptide of interest, such as a protein antigen.

Подробнее
04-04-2013 дата публикации

BINDING PARTNERS OF ANTIBODIES SPECIFIC FOR DENDRITIC CELL ANTIGENS

Номер: US20130085261A1

The present invention relates to the field of diagnostics, therapeutics and immunological reagents. More particularly, the present invention provides binding partners of antibodies specific for dendritic cell (DC) antigens. The present invention further provides diagnostic and/or therapeutic agent based on the binding partners or antibodies specific for the binding partners. 2. The isolated peptide of comprising an amino acid sequence selected from AQKYQ (SEQ ID NO: 2) or APKQQ (SEQ ID NO: 3).3. The isolated peptide of comprising the amino acid sequence set forth in SEQ ID NO: 2.4. The isolated peptide of comprising the amino acid sequence set forth in SEQ ID NO: 10.5. The isolated peptide of consisting of the amino acid sequence set forth in SEQ ID NO: 10.6. The peptide of for use in generating antibody which specifically binds CMRF44 antigen.7. The peptide of for use in screening for antibodies which specifically bind CMRF44 antigen.8. The peptide of for use in assessing binding specificity of a CMRF44-like antibody.9. The peptide of for use as a release agent in a method for selection of CMRF44 expressing cells. This application is a divisional application of U.S. patent application Ser. No. 11/721,425, filed Jan. 8, 2009, which is U.S. National Phase of International Application PCT/AU2005/001864, filed Dec. 9, 2005 designating the U.S. and published in English as WO 2006/060871 on Jun. 15, 2006, which claims priority to Australian Patent Application No. 2004907069 filed Dec. 10, 2004.1. Field of the InventionThe present invention relates generally to the field of diagnostics, therapeutics and immunological reagents. More particularly, the present invention provides binding partners of antibodies specific for dendritic cell (DC) antigens. The present invention further provides diagnostic and/or therapeutic agents based on the binding partners or antibodies specific for the binding partners.2. Description of the Prior ArtReference to any prior art in this ...

Подробнее
04-04-2013 дата публикации

CONTROL OF GROWTH AND REPAIR OF GASTRO-INTESTINAL TISSUES BY GASTROKINES AND INHIBITORS

Номер: US20130086701A1
Принадлежит: The University of Chicago

A novel group of gastrokines called Gastric Antrum Mucosal Protein is characterized. A member of the group is designated AMP-18. AMP-18 genomic DNA, cDNA and the AMP-18 protein are sequenced for human, mouse and pig. The AMP-18 protein and active peptides derived from it are cellular growth factors. Surprisingly, peptides capable of inhibiting the effects of the complete protein, are also derived from the AMP-18 protein. Cytoprotection and control of mammalian gastro-intestinal tissue growth and repair (restitution) is facilitated by the use of the proteins, making the proteins candidates for therapies in inflammatory bowel disease and gastric ulcers. 117-. (canceled)18. An inhibitor of a protein , the protein selected from a group of isolated homologous cellular growth stimulating proteins designated gastrokines , because the proteins are produced by gastric epithelial cells , the protein comprising a consensus amino acid sequence selected from the group consisting of VKE(K/Q)KXXGKGPGG(P/A)PPK(SEQ ID NO: 10) , VKE(K/Q)KLQGKGPGG(P/A)PPK(SEQ ID NO: 25) and VKE(K/Q)KGKGPGG(P/A)PPK(SEQ ID NO: 26) , and the inhibitor is selected from the group of peptides having an amino acid sequence consisting of KKTCIVHKMKK(SEQ ID NO: 14) and KKEVMPSIQSLDALVKEKK(SEQ ID NO: 15).19. A pharmaceutical composition used for the treatment of a gastro-intestinal disorder claim 18 , the composition comprising a growth stimulating peptide with a consensus sequence as in and derived from a gastrokine protein.20. A pharmaceutical composition for the treatment of diseases associated with overgrowth of gastric epithelia claim 18 , the compositions comprising an inhibitor according to .21. The pharmaceutical composition of claim 20 , wherein diseases are diseases of the colon and small intestine claim 20 , the diseases are selected from the group consisting of ulcerative colitis and Crohn's Disease.22. An isolated cDNA molecule encoding a human protein claim 20 , the protein having the amino acid ...

Подробнее
11-04-2013 дата публикации

COMPOSITIONS AND METHODS RELATED TO PROFILING A PLURALITY OF CELLS BASED ON PEPTIDE BINDING

Номер: US20130089498A1

Methods and compositions are described for classifying cells and/or peptides that associate or bind with a particular characteristic pattern to a plurality of cells or cell lines. Aspects of the invention also include the use of peptide(s) having an appropriate binding characteristic to deliver a drug to a cell or cell population. 131.-. (canceled)32. A method of targeting a therapeutic agent or an imaging agent to an EphA5 receptor positive cancer cell in a subject , the method comprising administering to the subject a pharmaceutical composition comprising:a) the EphA5 cell targeting moiety; andb) the therapeutic agent or the imaging agent.33. The method of claim 32 , wherein an EphA5 receptor is on a surface of the cancer cell.34. The method of claim 32 , wherein the subject is a human.35. The method of claim 32 , wherein the EphA5 cell targeting moiety comprises a peptide.36. The method of claim 35 , wherein the peptide is covalently modified.37. The method of claim 35 , wherein the peptide is cyclic.38. The method of claim 32 , wherein the EphA5 cell targeting moiety comprises an antibody.39. The method of claim 38 , wherein the antibody is specific for EphA5 receptor only when upregulated on a surface of the cancer cell.40. The method of claim 32 , wherein the therapeutic agent or the imaging agent comprises a radioisotope.41. The method of claim 40 ,wherein the radioisotope is Bi claim 40 , Pd claim 40 , Xe claim 40 , I claim 40 , Ge claim 40 , Co claim 40 , Zn claim 40 , Sr claim 40 , P claim 40 , S claim 40 , Y claim 40 , Sm claim 40 , Gd claim 40 , Yb claim 40 , Cr claim 40 , Mn claim 40 , Se claim 40 , Sn claim 40 , Sn claim 40 , Re claim 40 , Ho or Re.42. The method of claim 32 , wherein the therapeutic agent is a polypeptide capable of inducing cell death in the cell.43. The method of claim 32 , wherein the therapeutic agent is an immunotherapeutic agent.44. The method of claim 32 , Wherein the therapeutic agent is a chemotherapeutic agent.45. The method ...

Подробнее
11-04-2013 дата публикации

Light-Sensitive Ion-Passing Molecules

Номер: US20130090454A1
Принадлежит: Leland Stanford Junior University

The invention provides polynucleotides and methods for expressing light-activated proteins in animal cells and altering an action potential of the cells by optical stimulation. The invention also provides animal cells and non-human animals comprising cells expressing the light-activated proteins.

Подробнее
18-04-2013 дата публикации

Hyaluronic Acid Decomposition-Promoting Factor and Inhibitor Thereof

Номер: US20130095110A1
Принадлежит: KAO CORPORATION

The present invention is directed to KIAA1199, which is a novel factor involved in decomposition of hyaluronic acid, and to use thereof. More specifically, the invention is directed to a hyaluronic acid decomposition-promoting agent containing the KIAA1199 gene and a protein encoded by the gene; to a hyaluronic acid decomposition-inhibiting agent characterized by inhibiting the activity or expression thereof (including an siRNA or a monoclonal antibody); and to a method for screening a novel hyaluronic acid decomposition-controlling agent, in which the method contains employing the expression of KIAA1199 as an index. 1. A method for screening a hyaluronic acid decomposition-controlling agent , wherein the method comprises assessing a hyaluronic acid decomposition controlling effect of a test substance by use of cells in which a KIAA1199 gene is highly expressed transiently or stably.2. The method according to claim 1 , wherein the hyaluronic acid decomposition controlling effect of the test substance is assessed on the basis of the expression level of the KIAA1199 gene or a protein encoded by the KIAA1199 gene as an index.3. The method according to claim 1 , which comprises the following steps:1) culturing cells in the presence or absence of the test substance;2) determining the expression level of the KIAA1199 gene or a protein encoded by the KIAA1199 gene in the cells; and3) assessing the hyaluronic acid decomposition controlling effect of the test substance on the basis of the difference between the expression level of the KIAA1199 gene or the protein encoded by the KIAA1199 gene in the cells determined in the presence of the test substance and that determined in the absence of the test substance.4. The method according to claim 1 , which comprises the following steps:1) culturing cells in coexistence with a labeled hyaluronic acid in the presence or absence of the test substance;2) recovering a culture supernatant after culturing, and determining a molecular ...

Подробнее
18-04-2013 дата публикации

Peptides or Antibodies Which Bind to Melanoma Inhibitory Activity (MIA) Protein

Номер: US20130095122A1
Принадлежит:

The present invention relates to peptides and antibodies which bind to melanoma inhibitory activity protein and the uses of such peptides and antibodies. The invention also relates to nucleic acids coding for such peptides or antibodies. The invention also relates to pharmaceutical compositions comprising such peptides or antibodies or such nucleic acids. The present invention also relates to small molecule compounds which bind to melanoma inhibitory activity protein and to uses of such small molecule compounds. Moreover, the present invention also relates to a method of preventing dimerization and/or aggregation of melanoma inhibitory activity (MIA) protein. The invention is based on the identification of the relevant sites of interaction of the MIA protein with the inhibitory peptides/antibodies. Considering the amino acid sequence of this protein deprived from the signalling peptide, the residues involved in the interaction are selected from: A7, K53, G54, R55, R57, L58, F59, V64, Y69, R85, D87, K91, and more preferably C17, S18, Y47, G61, G66, D67, L76, W102, D103, C106. 122-. (canceled)23. A peptide or antibody that binds to melanoma inhibitory activity (MIA) protein and prevents dimerization and/or aggregation thereof , which peptide is not SEQ ID NO:46 or 47 , wherein binding of said peptide to MIA protein occurs at a surface of said MIA protein formed by at least three amino acid residues of said MIA protein selected from cysteine 17 , serine 18 , tyrosine 47 , glycine 61 , glycine 66 , aspartate 67 , leucine 76 , tryptophan 102 , aspartate 103 , cysteine 106 , valine 64 , tyrosine 69 , aspartate 87 , lysine 91 , glycine 54 , leucine 58 , phenylalanine 59 , alanine 7 , lysine 53 , arginine 55 , arginine 57 , arginine 85 , and lysine 94 , preferably cysteine 17 , serine 18 , tyrosine 47 , glycine 61 , glycine 66 , aspartate 67 , leucine 76 , tryptophan 102 , aspartate 103 , cysteine 106 , alanine 7 , lysine 53 , arginine 55 , arginine 57 , arginine 85 and ...

Подробнее
18-04-2013 дата публикации

New binder-drug conjugates (ADCs) and use thereof

Номер: US20130095123A1
Принадлежит:

The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target C4.4a, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practised as a monotherapy or else in combination with other medicaments or further therapeutic measures. 13. Compounds of the formulae (XXXa) and (XXXI) selected from the following group:N-[6-(3-{[(2R)-2-amino-2-carboxyethyl]sulphanyl}-2,5-dioxopyrrolidin-1-yl)hexyl]-N-methyl-L-valyl-N-[(3R,4S,5S)-1-{(2S)-2-[(1R,2R)-3-{[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino}-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide,N-[6-(3-{[(2R)-2-amino-2-carboxyethyl]sulphanyl}-2,5-dioxopyrrolidin-1-yl)hexyl]-N-methyl-L-valyl-N-[(3R,4S,5S)-1-{(2S)-2-[(1R,2R)-3-{[(2S)-3-(1H-indol-3-yl)-1-(1,2-oxazinan-2-yl)-1-oxopropan-2-yl]amino}-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide,N-(6-{[(5S)-5-amino-5-carboxypentyl]amino}-6-oxohexyl)-N-methyl-L-valyl-N-[(3R,4S,5S)-1-{(2S)-2-[(1R,2R)-3-{[(2S)-3-(1H-indol-3-yl)-1-(1,2-oxazinan-2-yl)-1-oxopropan-2-yl]amino}-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide trifluoroacetate,N-(6-{[(5S)-5-amino-5-carboxypentyl]amino}-6-oxohexyl)-N-methyl-L-valyl-N-[(3R,4S,5S)-1-{(2S)-2-[(1R,2R)-3-{[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino}-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide,and also their salts, solvates and solvates of the salts.16. Binder-drug conjugates according to or of the general formula (I) ,in whichn is ...

Подробнее
18-04-2013 дата публикации

ECT2 PEPTIDES AND VACCINES INCLUDING THE SAME

Номер: US20130095128A1
Принадлежит: ONCOTHERAPY SCIENCE INC

Isolated peptides derived from SEQ ID NO: 42 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines, are described herein. The inventive peptides encompass both the afore-mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite HLA binding and/or CTL inducibility of the original sequences. Further provided are nucleic acids encoding any of the aforementioned peptides as well as pharmaceutical agents, substances and/or compositions that include or incorporate any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find particular utility in the treatment of cancers and tumors, including, for example, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, esophageal cancer, NSCLC, lymphoma, pancreatic cancer, prostate cancer, renal carcinoma and SCLC. 1. (canceled)2. (canceled)3. (canceled)4. An isolated peptide selected from the group consisting of:(a) an isolated peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 3 and 21, and(b) an isolated peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 3 and 21, in which 1, 2, or several amino acid(s) are substituted, deleted, inserted or added.5. The isolated peptide of claim 4 , which consists of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 claim 4 , 3 and 21 claim 4 , wherein the peptide has one or both of the following characteristics:(a) the second amino acid from the N-terminus is selected from the group consisting of leucine or methionine; and(b) the C-terminal amino acid is selected ...

Подробнее
18-04-2013 дата публикации

BONE MORPHOGENIC PROTEIN BINDING PEPTIDE

Номер: US20130095139A1
Принадлежит:

A cyclized peptide designated BMP Binding Peptide (BBP) is a synthetic peptide that avidly binds rhBMP-2, as do endogenous forms of BBP, and sequence conservation between species results in a variety of useful BBP compositions. BBP increases the over-all osteogenic activity of rhBMP-2, increases the rate at which rhBMP-2 induces bone formation, and BBP induces calcification alone. Compositions and substrates including BBP, and methods of using BBP are useful in therapeutic, diagnostic and clinical applications requiring calcification and osteogenesis. 125-. (canceled)26. An article of manufacture comprising an implant , wherein said implant has a surface , and wherein said surface includes a peptide having the amino acid sequence of SEQ ID No. 13 , or a fragment thereof , wherein said peptide or fragment increases the degree or rate of osteogenesis or calcification in vertebrates.27. The article of manufacture of wherein the implant further includes one or more of TGF-beta claim 26 , BMP-2 claim 26 , BMP-4 claim 26 , BMP-7 or demineralized bone matrix.28. The article of manufacture of wherein the implant further includes mesenchymal stem cells.29. The article of manufacture of wherein the implant further includes chondrogenic or osteogenic precursor cells.30. The article of manufacture of wherein the mesenchymal stem cells secrete one or more growth factors.31. The article of manufacture of wherein the growth factor is a TGF-beta family member.32. The article of manufacture of wherein the chondrogenic or osteogenic precursor cells secrete one or more growth factors.33. The article of manufacture of wherein the growth factor is a TGF-beta family member.34. The article of manufacture of wherein said implant is formed into the shape of a pin claim 26 , screw claim 26 , plate claim 26 , or prosthetic joint.35. The article of manufacture of wherein said peptide is immobilized on the surface of said implant.36. An article of manufacture comprising a solid support claim 26 ...

Подробнее
18-04-2013 дата публикации

Compositions and methods for enhancing drug delivery across and into ocular tissues

Номер: US20130096069A1
Принадлежит: CellGate Inc

This invention provides compositions and methods for enhancing delivery of drugs and other agents across epithelial tissues, including into and across ocular tissues and the like. The compositions and methods are also useful for delivery across endothelial tissues, including the blood brain barrier. The compositions and methods employ a delivery enhancing transporter that has sufficient guanidino or amidino sidechain moieties to enhance delivery of a compound conjugated to the reagent across one or more layers of the tissue, compared to the non-conjugated compound. The delivery-enhancing polymers include, for example, poly-arginine molecules that are preferably between about 6 and 25 residues in length.

Подробнее
18-04-2013 дата публикации

Peptide targeting of inner ear cells

Номер: US20130096070A1
Принадлежит: University of Kansas

Peptide targeting moieties that target the cells of the inner ear can be used for targeted therapeutics. As such, nucleic acids and/or drugs can be associated with the targeting moieties in order to provide therapeutics that are delivered to specific cells in the inner ear. Conjugation of drugs or gene therapy vectors to cell specific peptides may allow the treatment of individual cell types within the inner ear. The peptide targeting moieties can be polypeptides having the sequences of Table 1 in an unnatural configuration. The polynucleotide can either consist of the sequence or include additional polypeptides attached to the ends of the sequences shown in Table 1. The polynucleotide can be in a non-native configuration. For example, the polypeptide is selected from the following: a-h-p-h-h-s-m (SEQ ID NO: 12); h-p-h-h-r-i-f (SEQ ID NO: 29); t-v-p-q-l-t-t (SEQ ID NO: 1); s-t-t-k-l-a-l (SEQ ID NO: 2); m-e-g-y-i-h-r (SEQ ID NO: 3); h-a-i-y-p-r-h (SEQ ID NO: 5); h-s-r-l-l-d-q (SEQ ID NO: 6); i-q-s-p-h-f-f (SEQ ID NO: 7); or y-a-a-h-r-s-h (SEQ ID NO: 8).

Подробнее
25-04-2013 дата публикации

LINEAR IGE PEPTIDE EPITOPES OF HAZELNUT ALLERGEN COR A 1 AND CELERY ANTIGEN API 1

Номер: US20130101624A1
Принадлежит: CHARITE UNIVERSITATSMEDIZIN BERLIN

Linear polypeptide epitopes of hazelnut cor a 1 and celery api 1.0101 allergen of a sequence length of ten to fifteen amino acids for treatment and prevention of hazelnut or celery allergy are provided. Means and methods for diagnosing hazelnut or celery allergy, and for detecting hazelnut or celery allergens in a sample, are also provided. 2. A polypeptide molecule according to claim 1 , for the treatment or prevention of hazelnut allergy.3. A pharmaceutical composition comprising one or more polypeptide molecule species according to claim 1 , for the treatment or prevention of hazelnut allergy.4. A polypeptide molecule having a sequence length of 10 claim 1 , 11 or 12 amino acids claim 1 , said polypeptide molecule having an amino acid sequence comprised as a contiguous sequence in SEQ ID 001 claim 1 , for use as a medicament.5. A polypeptide molecule having a sequence length of 10 claim 1 , 11 claim 1 , 12 claim 1 , 13 claim 1 , 14 or 15 amino acids claim 1 , said polypeptide molecule having an amino acid sequence comprised as a contiguous sequence in SEQ ID 012 claim 1 , SEQ ID 013 or SEQ ID 014 claim 1 , for the treatment or prevention of celery allergy.6. A pharmaceutical composition comprising one or more polypeptide molecule species as set forth in claim 4 , for the treatment or prevention of celery allergy.7. A method of diagnosing allergy against celery and/or hazelnut in a patient claim 4 , comprising the steps of{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'providing a polypeptide molecule having a sequence length of 10, 11, 12, 13, 14 or 15 amino acids, said polypeptide molecule having an amino acid sequence comprised as a contiguous sequence in any of the sequences of ,'}contacting said polypeptide molecule with a patient sample comprising IgE molecules ex-vivo under conditions allowing for the specific binding of IgE molecules to IgE epitopes, anddetermining whether said polypeptide molecule is specifically bound by an IgE molecule comprised in ...

Подробнее
25-04-2013 дата публикации

PEPTIDES USED IN THE TREATMENT AND/OR CARE OF THE SKIN, MUCOUS MEMBRANES AND/OR HAIR AND ITS USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS

Номер: US20130101662A1
Принадлежит:

Peptides of general formula (I): R—W—X-AA-AA-AA-AA-Y—Z—R(I) its stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, a preparation process, cosmetic or pharmaceutical compositions which contain them and their use in the treatment and/or care of the skin, mucous membranes and/or hair and the treatment and/or care of those conditions, disorders and/or diseases which are improved or prevented by Hsp stimulation. 1. A peptide of general formula (I){'br': None, 'sub': 1', 'm', '1', '2', '3', '4', 'p', 'q', '2, 'R—W—X-AA-AA-AA-AA-Y—Z—R\u2003\u2003(I)'}its stereoisomers, mixtures thereof and/or its cosmetically or pharmaceutically acceptable salts, wherein:{'sub': '1', 'AAis -His-;'}{'sub': '2', 'AAis selected from the group consisting of -His-, -Leu- and -Pro-'}{'sub': '3', 'AAis -Leu-;'}{'sub': '4', 'AAis selected from the group consisting of -Arg- and -Asn-;'}W, X, Y and Z are independently selected from amongst themselves from the group consisting of the codified amino acids and uncodified amino acids;n, m, p and q are independently selected from amongst themselves and have a value between 0 and 1;n+m+p+q is less or equal to 2;{'sub': 1', '5', '5, 'Ris selected from the group consisting of H, substituted or unsubstituted non-cyclic aliphatic group, substituted or unsubstituted alicyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl and R—CO— wherein Ris selected from the group consisting of H, substituted or unsubstituted non-cyclic aliphatic group, substituted or unsubstituted alicyclyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, substituted or unsubstituted heterocyclyl and substituted or unsubstituted heteroarylalkyl;'}{'sub': 2', '3', '4', '3', '3', '3', '4, 'Ris selected from the group consisting of —NRR, —ORand —SR, wherein Rand Rare independently selected from the group ...

Подробнее
25-04-2013 дата публикации

COMPOSITIONS AND METHODS FOR DETECTING AMYLOID-BETA-DEGRADING ENZYME ACTIVITY

Номер: US20130102498A1
Принадлежит: Academia Sinica

Novel substrates for detection of activity of amyloid beta degrading enzyme, such as Neprilysin (NEP) and insulin degrading enzyme (IDE), associated with Alzheimer's disease, are provided. A quenched fluorogenic peptide substrate containing the first seven residues of the Aβpeptide plus a C-terminal Cys residue to detect neprilysin activity with a fluorophore attached to the C-terminal Cys and a quencher linked to the N-terminus of the peptide is disclosed. An assay system sensitive to endopeptidase activity of NEP and IDE, but insensitive to other Aβ-degrading enzymes is disclosed. Active compounds are identified by a cell-based assay system for high-throughput screening. 1. A peptide substrate for detection of amyloid-β degrading enzyme activity , the substrate comprising:(a) a peptide of the sequence DAEFRHDC (SEQ ID NO: 1) comprising residues 1-7 of the amyloid-β peptide and a cysteine residue at the C-terminal end, or an analog or derivative thereof, wherein the peptide comprises a cleavage site for an amyloid-β degrading enzyme;(b) a quencher coupled to the N-terminal end of the peptide; and(c) a fluorophor coupled with the C-terminal end of the peptide.2. The substrate of claim 1 , wherein the amyloid-β degrading enzyme is selected from the group consisting of neprilysin (NEP) and insulin degrading enzyme (IDE).3. The substrate of claim 1 , wherein the fluorophore is selected from the group consisting of fluorescein claim 1 , fluorescein derivatives claim 1 , rhodamines claim 1 , tetramethylrhodamines claim 1 , coumarins claim 1 , resorufins claim 1 , pyrenes claim 1 , anthracenes claim 1 , phenylenes claim 1 , phthalocyanines claim 1 , cyanines claim 1 , xanthenes claim 1 , amidopyrylium dyes claim 1 , oxazines claim 1 , quadrain dyes claim 1 , carbopyronines claim 1 , NBD derivatives claim 1 , BODIPY fluorophores claim 1 , ALEXA fluorophores claim 1 , ALEXA-350 claim 1 , lanthanide chelates claim 1 , metalloporphyrins claim 1 , NIR fluorophores claim 1 , ...

Подробнее
25-04-2013 дата публикации

Inhibitors of protein kinases and uses thereof

Номер: US20130102522A1
Принадлежит: PHARMAGAP Inc

Compounds that are capable of inhibiting the activity of one or more protein kinases are provided. The compounds are short, predominantly basic peptidic compounds comprising between about 5 and about 20 amino acids, and can optionally comprise an ATP mimetic moiety. The protein kinase inhibiting compounds can be used to inhibit the activity of one or more protein kinases in vitro or in vivo. Also provided are methods of inhibiting a protein kinase in a subject by administration of an effective amount of a protein kinase inhibiting compound and the use of the protein kinase inhibiting compounds, alone or in combination with other chemotherapeutic agents, in the treatment of protein kinase mediated diseases and disorders.

Подробнее
25-04-2013 дата публикации

Compounds And Their Use

Номер: US20130102524A1
Принадлежит: NOVABIOTICS LIMITED

The present invention relates to peptides and their use in the treatment of microbial infections, in particular bacterial infections. In particular, the invention relates to peptides wherein at least 75% of the amino acids of the peptide are arginine and phenylalanine amino acids, at least 50% of the amino acids being arginine amino acids and at least 15% of the amino acids being phenylalanine amino acids. 1. A peptide wherein at least 75% of the amino acids of the peptide are arginine and phenylalanine amino acids , at least 50% of the amino acids being arginine amino acids and at least 15% of the amino acids being phenylalanine amino acids.2. The peptide of consisting of arginine and phenylalanine amino acids and zero to five non-arginine and non-phenylalanine substitutions.3. The peptide of comprising one or more substitution selected from the group consisting of lysine claim 2 , proline claim 2 , glycine and histidine.4. The peptide of consisting of arginine claim 3 , phenylalanine and one of the group consisting of lysine claim 3 , proline claim 3 , glycine and histidine.5. The peptide of consisting of arginine and phenylalanine amino acids.6. The peptide of comprising 3 to 200 amino acids.7. The peptide of consisting of 3 to 200 amino acids.8. The peptide of comprising an amino acid sequence selected from the group RRRFRFFFRFRRR (SEQ ID NO:) claim 6 , HHHFRFFFRFRRR (SEQ ID NO: 2) claim 6 , KKFPWRLRLRYGRR (SEQ ID NO: 3) claim 6 , RRRRRFFFRFRRR (SEQ ID NO: 4) claim 6 , RRRFRFRFRFRRR (SEQ. ID NO: 5) claim 6 , RRRFRFPFRFRRR (SEQ ID NO: 6) claim 6 , RRFRRFFFRRFRR (SEQ ID NO: 7) claim 6 , RRRRFFFRRRR (SEQ ID NO: 8) claim 6 , RRRRFRFRRRR claim 6 , (SEQ ID NO: 9) claim 6 , RRRRFPFRRRR (SEQ ID NO: 10) claim 6 , RRFRRRFRRFR (SEQ ID NO: 11) claim 6 , RRFRRRFRRFG (SEQ ID NO: 12) claim 6 , RRFGRRFRRFG (SEQ ID NO; 13) claim 6 , RRFRRFRRRFG (SEQ ID NO: 14) claim 6 , RRFRRFRRRFR (SEP ID NO: 15) claim 6 , FRRRRFFFRFRRR (SEQ ID NO: 16) claim 6 , RRRRRFFFRRRRF (SEQ ID NO: 17) ...

Подробнее
25-04-2013 дата публикации

PEPTOIDS AND METHODS FOR TREATING ALZHEIMER'S DISEASE

Номер: US20130102539A1
Принадлежит:

Provided herein are peptoids capable of inhibiting or reversing amyloid β (Aβ) fibril or plaque production. The peptoids form a helical structure with three monomers per helical turn and have at least two monomers with a side-chain having an arylalkyl group having the same chirality positioned such that the side-chains are on the same side of the peptoid. Also provided are methods of using the peptoids to inhibit or reverse aggregation of Aβ and methods of treating subjects with Alzheimer's disease (AD) or slowing the progression of AD. 1. A peptoid having the following formula: X—(—NR—CH—CO—)—Ywherein n is between 5 and 35,wherein X is H,{'sub': '2', 'wherein Y is selected from NH, H and OH,'}{'sub': '1', 'wherein Rof the peptoid is a branched or unbranched, saturated or unsaturated,'}{'sub': 1', '10, 'substituted or unsubstituted C-Calkyl group,'}{'sub': 2', 'n, 'wherein at least two R groups of R-Rof the peptoid comprise a branched arylalkyl group with either both (R) or (S) chiral centers, the aryl group may be substituted or unsubstituted,'}{'sub': 1', '10', '4', '10', '4', '10, 'wherein the remaining R groups are branched or unbranched, substituted or unsubstituted, saturated or unsaturated, C-Calky, C-Caryl, or C-Ccycloalkyl groups,'}wherein the peptoid forms a helical structure with 3 monomers per turn such that the at least two R groups comprising the arylalkyl groups are positioned on the same face of the peptoid,wherein at least three and up to 100% of the R groups with chiral centers have the same chirality.2. The peptoid of claim 1 , wherein x is 8.3. The peptoid of claim 2 , wherein four of the eight R groups are branched arylalkyl groups with either all (R) or all (S) chiral centers.4. The peptoid of claim 2 , wherein four of the eight R groups are (S)—N-(1-phenylethyl) or (R)—N-(-phenylethyl).5. The peptoid of claim 1 , wherein Ris a C-Caminoalkyl.6. The peptoid of claim 1 , wherein one half of the R groups have the same chirality.7. The peptoid of ...

Подробнее
25-04-2013 дата публикации

Use Of Tight Junction Antagonists To Treat Inflammatory Bowel Disease

Номер: US20130102547A1
Принадлежит: Alba Therapeutics Corp.

The present invention provides materials and methods for the treatment of inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis). Materials of the invention may include compositions comprising one or more tight junction antagonists and optionally one or more therapeutic agents. Methods of the invention may comprise treating a subject in need thereof with a composition comprising one or more tight junction antagonists and, optionally one or more therapeutic agents. 133-. (canceled)34. A method for treating Inflammatory Bowel Disease (IBD) in a patient , the method comprising:administering a peptide having the amino acid sequence GGVLVQPG (SEQ ID NO:15) to the colon of a patient having IBD.35. The method of claim 34 , wherein the peptide is administered in a delayed release composition that is stable in gastric fluid.36. The method of claim 34 , wherein the patient has Crohn's Disease.37. The method of claim 34 , wherein the patient has ulcerative colitis.38. The method of claim 34 , wherein the peptide is further administered to the small intestine of the patient.39. The method of claim 34 , further comprising claim 34 , administering an active agent selected from an aminosalicylate claim 34 , corticosteroid claim 34 , immunomodulator claim 34 , or antibiotic.40. The method of claim 39 , wherein the aminosalicylate is 5-aminosalicylic acid (5-ASA).41. The method of claim 34 , wherein the peptide is administered one or more times per day for a plurality of days.42. The method of claim 41 , wherein the peptide is administered chronically.43. The method of claim 34 , wherein the patient is not undergoing an acute Inflammatory Bowel Disease (IBD) attack at the time the peptide is administered.44. The method of claim 34 , wherein the patient is undergoing an acute attack of Inflammatory Bowel Disease (IBD) at the time the peptide is administered.45. The method of claim 34 , wherein the patient is a human.46. The method of claim 34 , wherein the patient ...

Подробнее
25-04-2013 дата публикации

METHODS FOR SELECTIVE TARGETING

Номер: US20130102757A1
Принадлежит: DANISCO US INC.

A selective targeting method is disclosed comprising contacting a library of ligands, particularly a peptide library, with an anti-target to allow the ligands to bind to the anti-target; separating the non-binding ligands from the anti-target bound ligands, contacting the non-binding anti-target ligands with a target allowing the unbound ligands to bind with the target to form a target-bound ligand complex; separating the target-bound ligand complex from ligands which do not bind to the target, and identifying the target-bound ligands on the target-bound ligand complex wherein the target-bound ligands have a Kin the range of about 10to 10M. Additionally claimed are the ligands identified according to the method. 1. A method for screening a peptide library comprising the steps of ,(a) contacting the peptide library with an anti-target to allow the peptides to bind with said anti-target;(b) separating unbound peptides;(c) contacting the unbound peptides with a selected target to allow said unbound peptides to bind with the target to form a target-bound peptide complex;(d) separating said target-bound peptide complex from peptides which do not bind to said target; and(e) identifying the target-bound peptides on the target-bound peptide complex.2. The method according to claim 1 , wherein step (a) claim 1 , (b) claim 1 , (c) or (d) is repeated between 2 to 10 times.3. (canceled)4. The method according to claim 1 , wherein said contacting step is in vivo.5. The method according to claim 1 , wherein said contacting step is in vitro.6. The method according to claim 1 , wherein the target-bound peptides bind with a selectivity corresponding to at least 10:1 and have a Kin the range of at least about 10M.7. The method according to claim 1 , wherein kis about 10secor less.8. The method according to claim 1 , wherein the identifying step comprises amplifying a nucleic acid coding for the target-bound peptide in a polymerase chain reaction.9. The method according to claim 1 , ...

Подробнее
25-04-2013 дата публикации

EZRIN ASSAY METHOD FOR THE IN VITRO DIAGNOSIS OF COLORECTAL CANCER

Номер: US20130102758A1
Принадлежит:

A method for the in vitro diagnosis of colorectal cancer by determining the presence of the Ezrin tumor marker in a biological sample taken from a patient suspected of having colorectal cancer using at least one anti-Ezrin monoclonal antibody directed against an Ezrin epitope chosen from the epitopes of sequence SEQ ID No.1, SEQ ID No.2, SEQ ID No.3, SEQ ID No.4+SEQ ID No.5, SEQ ID No.6+SEQ ID No.7 and SEQ ID No.8. Said method can be used for early diagnosis, screening, therapeutic follow-up and prognosis, and also for relapse diagnosis in relation to colorectal cancer. 1. An epitope comprising the amino acid sequence of SEQ ID No.1 , SEQ ID No.2 , SEQ ID No.3 , SEQ ID No.4+SEQ ID No.5 , SEQ ID No.6+SEQ ID No.7 , or SEQ ID No.8.2. The epitope of claim 1 , wherein the epitope comprises the amino acid sequence of SEQ ID No.1.3. The epitope of claim 1 , wherein the epitope comprises the amino acid sequence of SEQ ID No.2.4. The epitope of claim 1 , wherein the epitope comprises the amino acid sequence of SEQ ID No.3.5. The epitope of claim 1 , wherein the epitope comprises the amino acid sequence of SEQ ID No.4+SEQ ID No.5.6. The epitope of claim 1 , wherein the epitope comprises the amino acid sequence of SEQ ID No.6+SEQ ID No.7.7. The epitope of claim 1 , wherein the epitope comprises the amino acid sequence of SEQ ID No.8.8. An isolated antibody directed against the epitope of .9. The antibody of claim 8 , wherein the antibody is a monoclonal antibody.10. An isolated peptide comprising an amino acid sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID No.1 claim 8 , SEQ ID No.2 claim 8 , SEQ ID No.3 claim 8 , SEQ ID No.4+SEQ ID No.5 claim 8 , SEQ ID No.6+SEQ ID No.7 claim 8 , or SEQ ID No.8 claim 8 , wherein the peptide has at most 10 additional amino acid residues on either side of the amino acid sequence.11. The peptide of claim 10 , wherein the peptide comprises the amino acid sequence of SEQ ID No.1.12. The peptide of claim 10 , ...

Подробнее
02-05-2013 дата публикации

PEPTIDE DERIVATIVES, PREPARATION AND USES THEREOF

Номер: US20130108548A1
Принадлежит:

The invention relates to peptide derivatives (peptides and pseudo-peptides) and the use thereof as vectors for molecules of interest. The invention also relates to conjugates containing a peptide derivative of the invention bound to a molecule of interest. The peptides of the invention can be used, in particular, to vectorize, generally in the form of prodrug conjugates, molecules of pharmaceutical or diagnostic interest such as, for example, therapeutic molecules, imaging or diagnostic agents, or molecular probes, across cell membranes of different tissues or organs, healthy or pathologic, and in particular to enable their transport across physiological barriers of the nervous system such as the Blood brain barrier (BBB), Blood-spinal cord barrier (BSCB), or Blood-retinal barrier (BRB). 2. The peptide or pseudo-peptide of claim 1 , wherein A1 and A4 independently represent Cys or an analogue thereof selected from (D)-cys claim 1 , penicillamine (Pen) and (D)-penicillamine ((D)-Pen).3. The peptide or pseudo-peptide of claim 1 , wherein A2 represents a Pro analogue selected from pipecolic acid (Pip) and thiazolidine-4-carboxylic acid (Thz).4. The peptide or pseudo-peptide of claim 1 , wherein A3 represents Gly or sarcosin (Sar).6. The peptide or pseudo-peptide of claim 1 , characterized in that it is selected from a peptide having a sequence presented in anyone of SEQ ID NOs: 1 to 10 and 26 to 30.7. The peptide or pseudo-peptide of claim 1 , characterized in that it has a cyclic configuration.8. The peptide or pseudo-peptide of claim 1 , which binds human low-density lipoprotein receptor (hLDLR) on the surface of cell membranes.9. The peptide or pseudo-peptide of claim 1 , wherein said peptide or pseudo-peptide contains at least one peptidomimetic bond claim 1 , chosen from intercalation of a methylene (—CH—) or phosphate (—PO—) group claim 1 , secondary amine (—NH—) or oxygen (—O—) claim 1 , alpha-azapeptides claim 1 , alpha-alkylpeptides claim 1 , N-alkylpeptides ...

Подробнее
02-05-2013 дата публикации

Antibacterial and antifungal peptides

Номер: US20130108575A1
Принадлежит: C3 Jian Inc

This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.

Подробнее
02-05-2013 дата публикации

WOUND HEALING PEPTIDES AND METHODS OF USE THEREOF

Номер: US20130108614A1
Автор: HERMAN IRA M.
Принадлежит: TUFTS UNIVERSITY

The current invention relates to methods and compositions for the treatment of wounds in a mammalian subject. Particularly, the invention relates to novel polypeptides and encoding nucleic acids that stimulate keratinocyte and endothelial cell motility and/or proliferation. 1. (canceled)2. (canceled)3. (canceled)4. (canceled)5. (canceled)6. (canceled)7. (canceled)8. A method to promote wound healing in a subject in need thereof , comprising administering to the subject a peptide consisting essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs: 4-13.9. (canceled)10. (canceled)11. (canceled)12. (canceled)13. (canceled)14. (canceled)15. (canceled)16. (canceled)17. (canceled)18. (canceled)19. (canceled)20. (canceled)21. (canceled)22. (canceled)23. (canceled)24. (canceled)25. (canceled)26. The method of claim 8 , wherein the peptide is administered in an amount effective to enhance the rate of migration of keratinocytes or endothelial cells claim 8 , or a combination of keratinocytes and endothelial cells claim 8 , towards a wound edge.27. The method of claim 8 , wherein the administration of the peptide results in an increase in the re-epithelialization of the wound.28. The method of claim 8 , wherein the administration of the peptide results in an increase in angiogenesis in or near the wound.29. The method of claim 8 , wherein the peptide is administered at a wound site.30. The method of claim 8 , wherein the wound is a thermal claim 8 , chronic claim 8 , acute or surgical wound.31. The method of claim 8 , further comprising administering to the subject a second agent.32. The method of claim 31 , wherein the second agent is a polypeptide.33. The method of claim 31 , wherein the second agent is a growth factor claim 31 , cytokine claim 31 , or enzyme.34. The method of claim 31 , wherein the second agent is a non-human collagenase.35. The method of claim 34 , wherein the non-human collagenase is bacterial collagenase.36. The method of ...

Подробнее
02-05-2013 дата публикации

CDCA5 PEPTIDES AND VACCINES INCLUDING THE SAME

Номер: US20130108664A1
Принадлежит: Oncotherapy Science, Inc.

Isolated peptides derived from SEQ ID NO: 21 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines, are described herein. The inventive peptides encompass both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite HLA binding and/or CTL inducibility of the original sequences. Further provided are nucleic acids encoding any of the aforementioned peptides as well as pharmaceutical agents, substances and/or compositions that include or incorporate any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find particular utility in the treatment of cancers and tumors, including, for example, AML, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, esophagus cancer, gastric cancer, gastric diffuse-type cancer, lung cancer, lymphoma, prostate cancer, SCLC and soft tissue tumor. 13.-. (canceled)4. An isolated peptide selected from the group consisting of:(a) (a) an isolated peptide, which comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 9 and 16; and(b) an isolated peptide, wherein said peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 9 and 16, in which 1, 2, or several amino acid(s) are substituted, deleted, inserted, or added, provided said modified peptide retains the cytotoxic T lymphocytes (CTL) inducibility of the original peptide.5. The isolated peptide of claim 4 , wherein the peptide has one or both of the following characteristics:(a) the second amino acid from the N-terminus is selected from the group consisting of leucine and methionine; and(b) the ...

Подробнее
02-05-2013 дата публикации

Usp2a peptides and antibodies

Номер: US20130109587A1
Автор: Patrick J. Muraca
Принадлежит: Nuclea Biotechnologies Inc

The invention relates to novel USP2a peptides and antibodies, as well as nucleic acids related to them. The peptides, antibodies and the nucleic acids are useful for the detection, staging and monitoring of the progression of cancer, as well as for determining or monitoring the efficacy of treatment.

Подробнее
02-05-2013 дата публикации

Peptide-based inhibitor of interleukin-10 or interferon-gamma signaling

Номер: US20130109619A1

A peptide or peptidomimetic comprising an amino acid sequence based on conserved regions of IL10 or IFN-gamma receptor sequences, and related compounds and compositions, as well as methods for the use thereof to inhibit cytokine signaling.

Подробнее
02-05-2013 дата публикации

NOVEL PEPTIDE AND USE THEREOF

Номер: US20130109626A1
Принадлежит: ENSOLTEX CO., LTD.

The present invention provides a peptide represented by formula (I) of X-Leu-X-Leu-Xwherein Xrepresents Glu or Asp, Xrepresents His, Lys or Arg, Xrepresents Asp or Glu, with Glu, Asp, Leu, His, Lys and Arg being respectively glutamic acid, aspartic acid, leucine, histidine, lysine and arginine; or a pharmaceutically acceptable salt thereof; a composition for the treatment or prevention of at least one selected from cartilage damage and arthritis, containing the same peptide or a pharmaceutically acceptable salt thereof as an active ingredient; and a composition containing the same peptide or a pharmaceutically acceptable salt thereof and TGFβ1. The above-mentioned peptide or a pharmaceutically acceptable salt thereof is effective for the treatment and/or prevention of cartilage damage and/or arthritis and is capable of exhibiting effects of the regeneration of cartilage tissue, the inhibition of the expression of cartilage tissue matrix degrading enzyme and/or the inhibition of cartilage tissue ossification. 1. A peptide represented by formula (I):{'br': None, 'sub': 1', '2', '3, 'X-Leu-X-Leu-X\u2003\u2003(I)'}{'sub': 1', '2', '3, 'wherein Xrepresents Glu or Asp, Xrepresents His, Lys or Arg, Xrepresents Asp or Glu, with Glu, Asp, Leu, His, Lys and Arg being respectively glutamic acid, aspartic acid, leucine, histidine, lysine and arginine; or a pharmaceutically acceptable salt thereof.'}2. The peptide according to claim 1 , wherein Xrepresents Glu claim 1 , Xrepresents His claim 1 , and Xrepresents Asp.3. A composition for the treatment or prevention of at least one selected from cartilage damage and arthritis claim 1 , comprising the peptide of or a pharmaceutically acceptable salt thereof as an active ingredient.4. The composition according to claim 3 , wherein the treatment or prevention is by at least one selected from the regeneration of cartilage tissue claim 3 , the inhibition of the expression of cartilage tissue matrix degrading enzyme and the inhibition of ...

Подробнее
09-05-2013 дата публикации

GM1-LIKE PEPTIDES AND USES THEREOF

Номер: US20130115170A1
Принадлежит:

Compositions and methods relating to interfering with the interaction of gangliosides, such as GM1, with their ligands are provided. For example, methods are provided for treating infections by blocking the infectious agent from binding with GM1 using GM1-like peptides. Also provided are methods of inhibiting ligands from binding to GM 1 on the surface of cells and for neutralizing anti-GM1 antibodies in neurological diseases. 1. A peptide comprising SEQ ID NO:1 , SEQ ID NO:2 , SEQ ID NO:3 , SEQ ID NO:4 , SEQ ID NO:5 , or SEQ ID NO:6 , or a sequence comprising the amino acids of SEQ ID NO:1 , SEQ ID NO:2 , SEQ ID NO:3 , SEQ ID NO:4 , SEQ ID NO:5 , or SEQ ID NO:6 having one or more conservative substitutions.2. The peptide of claim 1 , wherein the peptide inhibits binding of a ligand to GM1 ganglioside.3. The peptide of claim 2 , wherein the ligand is an antibody or a bacterial protein.4. The peptide of wherein the peptide consists of SEQ ID NO:1 claim 1 , SEQ ID NO:2 claim 1 , SEQ ID NO:3 claim 1 , SEQ ID NO:4 claim 1 , SEQ ID NO:5 claim 1 , or SEQ ID NO:6.5. A composition comprising a peptide of .6. The composition of claim 5 , wherein the peptide mimics the carbohydrate epitope of GM1.7. The composition of claim 5 , wherein the peptide binds cholera toxin B subunit.8. The composition of claim 5 , wherein the peptide binds anti-GM1 antibodies.9. The composition of claim 5 , further comprising a therapeutic agent.10. The composition of claim 5 , further comprising a detectable agent.11. The composition of claim 1 , wherein the peptide is 50 amino acids or less.12. A method of inhibiting binding of a ligand to GM1 comprising administering an effective amount of a GM1-like peptide.13. The method of claim 12 , wherein the ligand is a bacterial protein.14. The method of claim 13 , wherein the bacterial protein is cholera toxin B subunit.15E. coli. The method of claim 13 , wherein the bacterial protein is heat-labile enterotoxin.16. The method of claim 12 , wherein the ...

Подробнее